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Severe symptomatic hyperlactataemia and lactic acidosis (Slll..A) are life-threatening events that are 
occurring at increasing incidence levels in South Africa. Globally, the rise in Slll..A cases is closely 
correlated to the increased accessibility of anti ret rovira I (ARV) medication for human immuno-
deficiency virus (HIV)I. Although hyperlactataemia and lactic acidosis were once thought of as rare 
conditions, they are now being recognized as important concerns when administering antiretroviral 
therapy. A better understanding of the risk factors for Slll..A is important in combating the morbidity 
and mortality associated with such an adverse event. 
Methods 
This is a matched case-control study with incidence density sampling. Cases were matched to controls 
according to ARV start date, duration on ARV therapy and facility. The population consists of people 
accessing ARV therapy in the public health care sector at G.F. Jooste Hospital and the five referral 
clinics in the G. F. Jooste drainage area between 1 August 2003 and 30 November 2005. Severe 
symptomatic hyperlactataemia was defined as having a serum lactate ~5 mmollL. Lactic acidosis was 
defined as having a venous standard bicarbonate <20 mmollL and a pH < 7.35 in addition to a serum 
lactate ~5 mmollL. Cases diagnosed with any other known causes of severe hyperlactataemia 
including sepsis, a history of alcoholism, thiamine deficiencies, severe hypoxia, dehydration or 
hepatitis were not included in the study. 
Results 
There were 71 cases referred to G.F. Jooste Hospital during the 27 month period. Ninety-five percent 
of the cases were diagnosed after being on ARV therapy between 6 to 18 months (range, 3-30 months). 
This particular cohort had a referral rate of 32.1 Slll..A cases and 16.8 lactic acidosis cases per 1000 
patient years at risk (each patient contributes time between their 6-18 month duration of risk on ARV 
therapy). Female sex (odds ratio [OR] 23.4; 95% confidence interval [Cll 4.0 - 136.6), weighing 
between 60 kilograms (kg) and 75 kg (OR 4.5; 95% CI 1.4 14.1), and especially ~ to 75 kg (OR 
23.39; 95% CI 4.00 - 136.63) at baseline and gaining ~ 6 kg in the first three months on therapy (OR 
3.5; 95% CI 1.3 - 9.5) are independent risk factors identifYing patients who may subsequently develop 
Slll..A. Weight loss of~ 3 kg (OR 11.53; 95% CI 3.0 44.6), experiencing at least one of the three 
major symptoms (vomiting, nausea or abdominal pains) ofSlll..A (OR 10.7; 95% CI 2.7 -42.0), 
together with gaining ~ 10 UIL of AL T since baseline (OR 12.4; 95% CI 1.8 85.4), are the clinical 
parameters that are most able to identifY patients about to develop Slll..A. Biochemical parameters 
reflecting acidosis at time of diagnosis are the only factors associated with acute mortality, whilst a 
raised creatinine of~ 77 mmollL (OR 17.8; 95% CI 2.8 - 113.2) at presentation is additionally 
associated with lactic acidosis. 
Conclusion 
It is recommended that overweight women not be started on a d4T containing ARV regimen. Early 
diagnosis is important in order to minimise morbidity and mortality from Slll..A. To facilitate early 
diagnosis, health care providers should be well versed on the risk factors related to this condition while 
maintaining a high index of suspicion when a patient has been on ARV therapy for between 6-18 
months. The World Health Organization's recommendation to decrease the dosage of d4T is expected 
to decrease incidence, but health care workers should remain alert as 4 cases in this study were on the 
decreased d4T dosage throughout their duration on ARV therapy. 
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1. Introduction 
Severe symptomatic hyperlactataemia and lactic acidosis (SHLA) is a life-threatening 
event that is occurring with increasing frequency in South Africa. Globally, the rise 
in SHLA cases is closely correlated to the increased accessibility of antiretroviral 
medication for human immuno-deficiency virus (HIV).i Although hyperlactataemia 
and lactic acidosis were once thought of as rare conditions, they are now being 
recognized as important concerns when administering antiretroviral therapy. 
In April of 2004, South Africa started a free antiretroviral therapy service in the public 
healthcare sector. By September of 2007, more than 31,000 people in the Western 
Cape alone had already been placed on antiretroviral therapy, and the numbers are 
continuously increasing. A better understanding of the risk factors for SHLA is 
important in combating the morbidity and mortality associated with such an adverse 
event. 
2. Background 
Antiretroviral (ARV) therapy has significantly improved the long term prognosis of 
patients infected with the human immunodeficiency virus (HIV).2-4 However, the 
widespread use of ARV therapy has led to an increase in sometimes fatal adverse 
events.2.4 SHLA is one of the uncommon, but more serious and often fatal 
complications related to the wide-spread use of ARV therapy?·4-6 
Currently, not enough is known about the risk factors leading to SHLA to accurately 
identify high risk patients who may potentially progress to such conditions. The onset 
of SHLA can be sub-acute for months, with or without symptoms similar to other 
complications related to HIV infection, or it can be acute and fulminant.4 The latter 
cases can lead to multi-organ dysfunction and heart failure within hours.4,7 
The diagnosis of hyperlactataemia depends on serum lactate measurements. Previous 
studies suggest that many patients receiving highly active antiretroviral therapy 
(HAART) may reach new higher, but stable lactate levels during treatment.2,4,6 One 
prospective study found that many of the patients with higher blood lactate elevations 
during therapy remained at the higher stable levels for the three year duration of the 
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study.4,6 The majority of patients diagnosed with higher lactate levels remain 
asymptomatic, without progression to a more severe state of SHLA. The homeostatic 
mechanisms may be preserved enough in these patients to compensate for mild lactate 
excess.2,4 Therefore, the use of raised serum lactate levels to predict subsequent 
severe hyperlactataemia has been shown to have a poor positive predictor value,2,4,7 
with one study reporting this value to be 39%.8 Routine surveillance of serum lactate 
levels for the general population receiving ARV therapy is a costly tool, providing 
limited benefits with the current knowledge available, obviating the need for routine 
testing in asymptomatic patients.4,6,7,8,9 
2.1. Classification 
Unstressed patients have a normal lactate concentration of 1-1.5 mmollL. 1O 
Hyperlactataemia is clinically defined as a serum lactate concentration between 2.5 
and 5 mmollL, while severe symptomatic hyperlactataemia (SH) is denoted as a 
serum lactate greater than or equal to 5mmllL with accompanying symptoms. Lactic 
acidosis (LA) is defined as the combination of an elevated lactate level ~ 5 mmollL 
and associated metabolic acidosis (pH < 7.35 and bicarbonate concentration < 20 
mmollL).7,9 
2.2. Prevalence and Incidence 
Nucleoside reverse transcriptase inhibitor (NRTI) associated hyperlactataemia can 
present both with and without symptoms. Previous studies have indicated a 
prevalence of increased serum levels to be between 10-35%, while the prevalence of 
SH makes up 0.8-3% of that figure.2,9 The prevalence of SH was estimated to be 1.3 
cases per 1,000 person years in a retrospective study between 1989 and 1994. 
However, more recent studies have indicated rates up to 20.9 cases per 1000 person 
years. I,3 In South Africa, McCord's ARV clinic and the Khayalitsha programme 
recently reported incidence rates of 17-19 cases per 1,000 person years on d4T .11 
High rates of stavudine usage in resource poor countries, more accessible supplies of 
ARV therapy, better informed clinicians and patients, and more evidence associating 
NRTIs with hyperlactataemia may contribute to the recent rise in the number of 
detected cases. I Severe hyperlactataemia with metabolic acidosis (LA) has a reported 
mortality rate of 40 to 60%, and can rise to greater than 80% in patients with lactate 
measures in excess of 10mmoi/l. 2,4,9,12 
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2.3. Clinical Symptoms and associated conditions 
A review of studies has shown that symptoms of hyperlactataemia are non-specific 
and generally similar to the more severe forms of SH and LA.2,4 Studies of 
hyperiactataemia have shown symptoms to include malaise, asthenia, hepatomegaly, 
weight loss and gastrointestinal complaints such as nausea, vomiting and abdominal 
pain.2,4,6 LA includes the above symptoms plus tachyponea, dysponea, cardiac 
arrhythmia, seizures, abnormal mentation and renal or heart failure.2,4 Many of the 
milder symptoms are also commonly associated with HIV infection, which may lead 
to a delayed diagnosis reSUlting in increased morbidity and mortality. The more 
severe symptoms, such as dysponea and tachyponea present themselves too late for 
predictive tools, when effects may not be reversible? 
SHLA has been correlated with NRTI use, hepatic macro and microvesicular 
steatosis, liver dysfunction and fulminant liver failure.2,4,6,9 More recently, reports 
have associated LA with the occurrence of myopathy, cardiomyopathy, neuropathy, 
pancreatitis, lipoatrophy and pancytopaenia ?,6 It is still unclear whether 
hyperiactataemia is a cause of or only highly correlated to these conditions. 
2.4. Risk factors and Predictors 
The rarity of SHLA suggests that many factors must co-exist in order for such 
conditions to occur.4 The functioning and number of mitochondria, the level of 
damage due to co-morbid infections and their medications, metabolic abnormalities 
and liver damage are likely factors that affect the outcome of SHLA.4,6,7 
Reaimens 
At least 43 in vitro and animal studies have shown that all NRTIs promote 
hyperiactataemia, however the inhibition of mitochondrial deoxyribonucleic acid 
(mtDNA) polymerase y varies according to the affinity of the NRTls' nucleoside 
analogues for the enzyme.1,2,4,13 The NRTls have been ranked according to their 
ability of reducing mtDNA content during in vitro studies as follows: "zalcitabine 
(ddC) >didanosine (ddI) >stavudine (d4n >lamivudine (3TC) > nevirapine (NVP) > 
zidovudine (AZT) > abacavir (ABC) = tenofovir (TDF)".2 Controversy in tenofovir's 
inhibitory potency exists with Day's study reporting greater affinity of TDF in 
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comparison with AZT and ABC.4 Another in vitro study reported that the combined 
effects of d4T/3TC were more pronounced than those of either NRTI alone indicating 
possible synergistic mitochondrial toxicity .14 Most studies agree that the prevalence 
of SHLA is highly correlated to ddI and d4T use. I-3,6,9,12,\3,15 Marceau and colleagues 
reported statistically significant (p<0.05) odds ratios (OR) for d4T and ddI as 2.5 and 
3.1 respectively,9 while a literature review of75 cases reported 76% of the patients on 
d4T.1 The high percentage of reported cases on d4T in comparison to ddI is most 
like ly due to the greater use of d4 T in ARV regimens. Most cases of SHLA manifest 
between 3 to 20 months duration on NRTI's.4,16 Symptoms of SHLA are reported to 
recede when NRTIs are discontinued.3,7,12 
Patient Profile 
Female gender, age and obesity have been inconsistently reported as risk factors for 
SHLA, although the small number of cases during analysis may be a contributing 
factor. Most bigger studies and reviews report females at a greater risk,I,2.4.7.9,15,17 
older age was reported as being associated to hyperlactataemia in two studies,9,18 
while obesity or high body mass index was suggested in two reviews to have possible 
correlations with hyperlactataemia. 15,17 A further study in South Africa by Boulle et 
at. found a baseline weight between 60 and 75 kilograms (kg) to be independently 
associated with d4T substitutions due to SHLA in comparison to patients on ARV 
therapy weighing less than 60 kg.16 Pregnancy was also reported to be a risk factor 
for SH in one study. 2 
Rapid weight gain and loss, parental malnutrition and current malnutrition all have 
been reported to be associated with the development of non-alcoholic fatty liver 
disease. 19 
Clinical siKns symptoms and manifestations 
A literature review of 75 cases of LA reported gastrointestinal symptoms (abdominal 
pain, vomiting, nausea and diarrhoea) as the number one complaint affecting over 
77% of the patients.! Respiratory symptoms (cough and dyspnoea) and muscular 
symptoms (asthenia and malaise) have also been widely reported .1,2,7-9,15 
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Liver abnormalities are a common feature in patients with hyperlactataemia. A 
significant difference in transaminase, bilirubin and bicarbonate levels were found in 
patients with normolactatemia compared to those with hyperlactataemia.2,7,9,13 While 
hepatitis Band C viruses have been poorly studied in patients with hyperlactataemia, 
some correlations have been found.4,7 One case-control study in France reported 66% 
of LA patients to be co-infected with hepatitis. 15 Anti-tuberculosis therapy has also 
been linked to liver damage,20 and should be considered as HIV and TB co-infection 
is prevalent in South Africa. 
As the kidneys are lactate consumers, kidney impairment may be a contributor to 
SHLA. One study found a low nadir CD4 count less than 250 cells/mm3 (OR 8.4; 
95% confidence interval [CIl 1.2- 00) and low creatinine clearance (OR 15.8; 95% CI 
(3.0 - 86.5) at baseline the only significant factors for LA, suggesting a link between 
impaired kidney functioning and LA. 15 However two other studies reported no 
significant association between creatinine levels and hyperlactataemia.7,9 
Additionally, studies have reported concurrent infectious illness at presentation of 
SH.7 
Metabolic disorders including lipoatrophy, elevated triglycerides, insulin resistance, 
and C-peptide levels have been shown to be significantly associated to 
hyperlactataemia in some studies.7,9,15 Diabetes has been reported in several cases of 
LA.2,9 
Peripheral neuropathy and myopathy are only more recently being looked at in 
relation to hyperlactataemia patients and possibly result from mitochondrial toxicity. 
Although studies have reported frequencies of such conditions, the degree of 
association in patients with SHLA has not been reported.3,7,8 
2.5. Physiology 
The mechanisms describing the relationship of known risk factors with SHLA are not 
fully understood, but there are quite a few possible pathways described below. 
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Lactate is normally found at low concentrations in the body and is a product of 
glycolysis under anaerobic conditions. It is produced in most tissues and cleared 
mainly by the liver and kidneys. Additional uptake by the skeletal muscles and lungs 
can take place when increased production occurs .2,4 Decreased mtDNA, disruption 
of the metabolic metabolism through oxidative phosphorylation, and liver or kidney 
disease can all disrupt the homeostatic controls that keep lactate at normal levels 
within the body.4 
Mitochondrial toxicity 
Recent studies have shown that NR Tis can theoretically cause mitochondria] 
toxicity.2,4,5,13 NRTIs prevent DNA elongation and viral reproduction of the HIV 
virus by their affinity to reverse transcriptase.3 NRTIs are nucleoside analogues that 
become nucleotides after intercellular triphosphorylation. They are then incorporated 
via the viral reverse transcriptase enzyme into the viral DNA chain, halting 
transcription and replication ofHIV.3 
NRTIs also have the potential to act in the same destructive way in the mitochondria, 
inducing toxicity by inhibiting DNA}' polymerase.3,7,9,15 The physiological 
concentrations ofNRTIs minimally inhibit nuclear polymerases, but mitochondrial 
DNA}' polymerase seems more susceptible to such inhibition.4,7 This is the only 
enzyme involved in the replication of mtDNA, causing mitochondrial depletion and 
structural changes to the mitochondrial genome.4,7,9,10 Alterations in the 
mitochondrial genome further cause disruptions in the normal functioning of the 
respiratory chain, which takes place within the mitochondria.4 
One of the necessary functions of the mitochondria is to convert pyruvate (an end 
product of glycolysis) into carbon dioxide and the cellular fuel adenosine triphosphate 
(ATP).6,9,1O During this process, most of the pyruvate is converted into 
acetyl coenzyme A, which enters the tricarboxyHc acid cycle to form nicotinamide 
adenine dinucleotide (NADH). The mitochondria use the NADH through oxidative 
phosphorylation to produce ATP,3,21 When the numbers of mitochondria are 
decreased or not functioning normally due to impaired oxidation, pyruvate is instead 
converted by lactate dehydrogenase into lactate, outside of the mitochondria. As the 
deterioration of the mitochondria continues, decreases in ATP production ensue, and 
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an accumulation of lactic acid transpires .3,4,15 SHLA results from an increase in 
serum lactate levels that other organs such as the liver and kidneys cannot compensate 
for.4,I0,22 
Although many studies are in agreement with the theory ofNRTI toxicity leading to 
depletion in mtDNA, there has been a case report of a patient with a marked reduction 
in respiratory chain enzymes but not mtDNA depletion.s It has also been reported that 
HIV infection is a risk factor for mitochondrial death. HIV infected patients, whom 
have never been on NR TIs, have shown significantly lower ratios of mitochondrial to 
nuclear DNA. The depletion of mitochondria may make HIV infected people more 
susceptible to further mitochondrial damage when treated with NRTI therapy.3 
Hepatic Steatosis 
Hepatic Steatosis is a common pathological finding thought to occur in 20-30% of the 
adult population in the United States.4,19,23,24 Although global prevalence has not yet 
been determined, it is thought to occur in 10 - 30% of various populations.19,24 This 
condition affects all races and ethnic groups and does not have any age or gender 
prerequisites. However, prevalence figures have been reported to increase 
significantly up to 57 - 74% in obese individuals. 19 Hepatic steatosis along with LA 
presents the most fulminant cases of ARV toxicity.4 If steatosis presumably occurs in 
10 - 30% of the general population of South Africa, a closer look is needed into the 
synergies between mitochondrial toxicity and hepatic steatosis, as well as the affects 
steatosis may have, on its own, in lactic acid production. 
Steatosis (fatty liver) is often asymptomatic and is characterized by excess fat (> 5%) 
accumulation in the parenchyma of the Iiver.4,19,23 Laboratory results such as 
increased levels of serum aminotransferases, elevated lipid profiles and glucose 
concentrations can all give a clinician a high index of suspicion for steatosis,7.19,2S but 
only a liver biopsy can confirm such a diagnosis.19 As effective medical therapy is 
lacking for steatosis, and the risks high for biopsy, such confirmation is highly 
debated. 19 Although non-alcoholic fatty liver disease (NAFLD) is thought to be a 
common component ofSHLA, its frequency in HIV infected patients is not known.2,4 
There have been cases of LA without steatosis found during biopsy of the liver 
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suggesting that LA and hepatic steatosis may occur independently;2 however it seems 
likely that ARV therapy plays a role in increasing the likelihood of steatosis.2.4 
Tumour necrosis factor-alpha (TNF-a), a pro-poptotic cytokine which may act on the 
mitochondria, has been seen to be elevated in individuals on ARV therapy.7 Previous 
studies have also shown that patients treated with NRTls exhibiting peripheral 
lipoatrophy have significantly increased numbers of serum triglycerides, insulin, C-
peptide levels and hepatic fat content.2,4,7,14 
There may be mUltiple pathways in which HIV infection and HAART promote 
NAFLD. Damage to the liver has been hypothesized as a two level process. The first 
damage occurs during mitochondrial depletion resulting in an imbalance in lipid 
homeostasis, which may be aggravated by insulin excess.4,19 During times of insulin 
excess, free fatty acids are released through lypolysis in adipose tissue, triggering 
increased hepatic fatty acid synthesis while oxidation is inhibited.4,19 Free fatty acids 
then accumulate, only to be metabolized to triglycerides.3 Furthermore, export of 
very low-density lipid proteins from the liver is impaired.4 This results in 
accumulation of fat in the liver.1,4,21 The second level of damage occurs during 
oxidative stress from mitochondrial toxicity and cytokine mediated hepatocellular 
damage, causing non-alcoholic steatohepatitis (NASH - a more serious level of 
NAFLD).4.19 As LA almost always occurs with hepatic steatosis, the extent of 
mitochondrial toxicity in the hepatoctyes may be a key factor for progressing into a 
state ofSHLA in NRTI treated patients.6 
2.6. Previous study designs 
The majority of published studies on SHLA describe a case or series of cases within a 
health facility or larger cohort (cases being described as having raised lactates, SH or 
LA). 1,8,26·30,31 During a literature search five studies published after the year 2000 
were found that compared exposures amongst patients with and without the outcomes 
of raised lactates, SH and/or LA using various forms of cohort analysis.9,18, 32·34 Only 
two case-control studies were found, one comparing LA and one comparing raised 
lactates (>3.5 mmolll) against controls on ARV therapy. 13,15 
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Two of the case series studies were carried out in South Africa and were nested within 
larger cohorts. Both studies described incidence levels of symptomatic 
hyperlactataemia and/or LA (Geddes et al reported 19 cases of LA per 1000 patient 
years of treatment, and Bolhaar et al reported 10.6 cases of LA and 20.2 cases of 
symptomatic hyperlactataemia (lactate 2:4.5 mmollL) per 1000 patient years on 
treatment). These studies further described the clinical and demographic variables of 
the cases at baseline and at diagnosis, without comparison to controls. Both studies 
also described symptoms experienced at case presentation?7,28 
Of the five cohort analyses, four looked at exposures associated with raised serum 
lactates (two compared exposures of patients with lactates 2: 2 mmollL against 
exposures of patients with lower lactates and two considered lactates 2:2.25 mmollL as 
the threshold) 9,18,32,34. The main objectives of these four studies were to describe the 
incidence of raised serum lactates in their population, describe risk factors associated 
with a raised serum lactates and one also assessed the utility of routine lactates for 
ARV safety monitoring. As it has been shown in these and other studies that raised 
serum lactate levels are poor predictors of future SHLA,2.4,7,8,9,18,33 risk factors 
identified with such an outcome may not be wholly relevant in preventing the 
morbidity and mortality connected with SHLA. 
Only one of the cohort studies looked at exposures associated with a serum lactate> 5 
mmoill. This large study of 1566 participants from the Swiss HIV Cohort reported 49 
cases ofSH and may have been the only study powerful enough (a large enough 
sample size) to look at associations between exposures and the rare outcome ofSH. 
Although many baseline characteristics and ARV drugs during follow-up were 
analysed, only specific ARV drugs were found to be independently associated with 
SH during multivariate analysis.33 
Both case-control studies looked at baseline information and last laboratory results 
before case diagnosis and/or at the end of the study period (for controls in the un-
matched case control study). The matched case-control by Datta et al. found d4T to 
be the only independent variable associated with a lactate 2: 3.5 mmollL. Cases in this 
study were matched according to inclusion criteria (at least two lactate measurements, 
on ARV therapy for at least 4 months and stable on treatment at the time of the study) 
Background > Previous study designs 9 
and did not necessarily constitute a true matched case-control in the traditional sense 
(matching by variable). A small sample size (21 cases and 42 controls), limited 
variables and a low lactate threshold may have all contributed to having found only 
one variable associated with SHLA. J3 
The second case-control study presented by Bonnet et al. reported that a low baseline 
CD4 count and a creatinine clearance <70 mLimin (taken within one month prior to 
diagnosis) were associated with lactic acidosis during crude analysis (lactate >5 
mmollL and a plasma pH of <7.38). Multivariate analysis was not carried out and 
may not have been done due to the small sample size (9 cases and 41 controls). This 
case-control study also described symptoms amongst the cases at the time of 
diagnosis. 15 
A third case-control study is currently under-way, collecting cases and controls 
internationally. This case-control study by Arenas-Pinto et al. will have the advantage 
of many diagnostic tests not available in the South African context (imaging results, 
biopsies and mitochondrial function tests).35 
The cohort studies were extremely important in describing the effects of different 
ARV drugs on serum lactate levels, and were also very important in trying to 
understand the epidemiology of raised serum lactates in an HIV -infected population 
on ARV therapy. The case-control studies showed further proof of association 
between stavudine and SHLA. There are, however, still many gaps left in the 
knowledge of risk factors contributing towards SHLA. 
Further more, none of the studies looking at SHLA considered clinical variables or 
symptoms during follow-up, with the exception of one study which looked at lactate 
levels at stated intervals. 
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3. Aim 
The aim of this study was to identify baseline risk factors and possible associations 
during clinical follow-up for severe symptomatic hyperlactataemia and lactic acidosis 
in a Southern African public health sector treatment programme. 
4. Objectives 
1. To describe the study population and differences in characteristics between the 
cases and matched controls at baseline and during foHow-up appointments 
leading to case diagnosis. 
2. To characterise the cases and to look for associations related to the severity of 
SHLA and mortality within this sub-set of study participants. 
3. To describe the number of cases being referred to a.F. Jooste Secondary 
Referral Clinic from within the provincially demarcated referral area in 
relation to the patient years of ARV therapy at the referral clinics. 
4. To look for associations with SHLA in variables collected at initiation of ARV 
therapy and the first few months of care before manifestations of signs and 
symptoms occur in hopes to identify risk factors to be aware of when making 
decisions on ARV regimen choices. 
5. To look for associations between clinical parameters recorded during foHow-
up consultations and SHLA. 
5. Hypotheses 
1. Specific patient characteristics may put a person at a greater risk of developing 
SHLA including baseline weight and gender. 
2. Rapid weight gain may further exacerbate lactic build up in patients at risk of 
SHLA. 
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6. Methods 
6.1. Study Design 
This was a matched case-control study with incidence density sampling. As SHLA is 
rare, a case-control study design proved to be the most efficient way of analysing risk 
factors. The case-control study is nested within the larger cohort of ARV patients 
attending public ARV services in the Western Cape Province. 
Although matching may not be the first choice when conceiving a study design, 
logistics made this technique the most feasible. The monitoring programme in the 
Western Cape, South Africa does not have a central location where details of all 
patients initiated on ARVs are kept. The information at central level is aggregated, 
with registers containing patient information kept at facility level. As it was not 
practical to build a database for purposes of random sampling to incorporate all 
patients in the Western Cape, or at least patients from the sites cases were referred 
from, the decision that controls be matched by health care site was made. Duration on 
ARV therapy also proved a problem, as the literature review and local knowledge 
showed that the duration on ARV therapy, in particular on d4t and ddI containing 
regimens was a risk factor for SHLA. As the ARV rollout in the Western Cape was 
continuously growing, a direct random sample of controls at facility level would have 
meant the study would sample more controls at the beginning stages of ARV therapy 
compared to controls at longer durations. In addition, patients were recorded at most 
facilities using a paper-based register, with names recorded chronologically by ARV 
start date. For these two reasons, matching by ARV duration and commencement 
date was the most plausible method. Therefore, the controls were matched to the 
cases according to ARV commencement month, duration on an AR V regimen and 
facility. As patients were matched by facility, this had the added benefit that controls 
may come from relatively the same socio-economic status. Beside the benefits due to 
practicality, matching also limited possible confounding factors pertaining to different 
management characteristics between the facilities, drug durations and policies that 
may have changed over time. 
The registers placed at each ARV health facility keep track of all patients receiving 
care at the facility and is updated on a monthly basis. This allowed for easy 
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determination of the status of a randomly selected control at the time of the matched 
cases' month of diagnosis. As incidence density sampling for case-control studies 
most closely reflects the rate ratio, and sampling in this way was feasible, it was 
decided to use this type of control sampling method. 
6.2. Population 
The population consisted of people accessing ARV therapy in the public health care 
sector with referral routes to the G.F. Jooste Hospital Secondary Referral Clinic. The 
drainage area for G.F. Jooste hospital includes the infectious disease clinic within the 
hospital and the five surrounding primary health care fac'ilities with ARV services 
including Site B and Site C Community Health Centres in Khayalitsha, Gugulethu 
Community Health Centre, Mitchells Plain Community Health Centre and Crossroads 
Community Health Centre. All of these facilities are ARV dedicated sites in the 
Western Cape, South Africa. 
Inclusion Criteria: 
• Symptomatic cases were referred to the G.F. Jooste Secondary Referral Clinic 
between 1 August 2003 and 30 November 2005 
• Cases needed a confirmed blood lactate level 2: 5 mmollL 
• Patients included in the study needed to be at least 18 years of age 
Exclusion Criteria: 
• Patients diagnosed with any other known causes of SHLA including sepsis, a 
history of alcoholism, thiamine deficiencies, severe hypoxia, dehydration or 
hepatitis. 
• Treatment experienced patients whom are defined as interrupting ARV 
therapy for greater than one month with inaccessible details of their previous 
ARV treatment history. 
• Controls not remaining in care within the ARV services at the date of the 
matched case's SHLA presentation date. 
6.3. Sampling size 
All eligible cases diagnosed with SHLA between 1 August 2003 and 30 November 
2005 were included in the study. 
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This study was restricted by the size of the case-series study generated at G.F. Jooste 
Hospital. At the time the proposal to ethics was written, 50 cases had already been 
diagnosed. As the determined study period included several more months, we 
projected that at least 65 patients' folders would be available for review and inclusion 
to both the case-series and case-control study. 
Although the study was restricted by the number of cases that could be included, the 
following sample size calculations deduced that the sample size would be adequate to 
answer the hypotheses. Given the small number of cases, two controls were sampled 
for every case to increase statistical power. With 50 cases and 100 controls, the study 
would had 0.80% power to detect a 10% difference in the proportion of cases and 
controls with weights over 80kg, premised on 7.5% of controls being over 80kg 
(based on existing Khayelitsha cohort data). 
6.4. Sampling Strategy 
·Cases 
All cases ofSHLA that had a confirmed diagnosis at G. F. Jooste Hospital and met 
the eligibility criteria were included in the study. 
Controls 
Two controls for every case were sampled. The controls were systematically selected 
from the same cohort (the same month commencing ARVs and at the same clinic) as 
each case. The controls were selected by using the ARV registers held in each of the 
facilities offering ARV services within the public health sector. 
At the facilities where the ARV register was paper-based, each case was located 
within the register according to the month they started ARV therapy. The first patient 
listed after each case was counted as number one, with each patient listed thereafter as 
the next chronological number. The fourth and the tenth person listed after each case, 
if eligible, became part of the study. If the systematically selected control was not 
eligible, the next person listed in the register was chosen. All determined cases were 
skipped in the enumerating process. If, during counting, the end of the cohort of 
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people was reached, the counting continued at the beginning of the same cohort once 
again, skipping the cases. Paper-based registers are placed at G.F. Jooste Hospital, 
Mitchell's Plain Community Health Centre, Crossroads Community Health Center, 
Robbie Nurrock Community Health Centre. 
Medecins Sans Frontieres supports an electronic ARV database within the 
Khayelitsha sub-district, while the Desmond Tutu Foundation supports an electronic 
database for the Guguletu Community Health Centre. The facilities offering ARV 
services within the Khayelitsha sub-district include Site B and Nolungile Community 
Health Centres. Controls were sampled from the electronic register in a similar way 
to the paper-based registers. Once a case was found within the database, the database 
was filtered for the same clinic and ARV commencement month. The database was 
then sorted according to start date and the controls were selected according to the 
fourth and tenth eligible person listed after the case. 
Although the selection of controls was intended to be done without replacement, this 
was not always the case. Facilities starting up new ARV services often started very 
small, initiating only a few people in the beginning months. Due to this, four controls 
had to be re-sampled as all other patients in the same cohort were either a case or 
ineligible participant. 
6.5. Data Collection 
Tools 
A Microsoft Access™ database was developed to collect all of the information 
gleaned from the patients' folders. 
Variables 
All variable data for the study was collected retrospectively, using the ARV registers 
at the clinics and the selected patients' folders. All information collected from the 
records of each patient was related to the time period while the patient was receiving 
care within the ARV services. Data was collected for all cases up to the point of 
diagnosis, and for the controls up to the last follow-up appointment in the month of 
the matched case diagnosis date. 
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The ARV register provided the folder number, name and ARV commencement date 
of each participant. The patients' folders at the primary health care facility were 
accessed to collect all further information used for analysis within this study, with the 
exception of the clinical findings on the date of case diagnosis at the G. F. Jooste 
Secondary Referral Clinic. Information collected from the patient's folder included 
demographic information (date of birth and sex), the WHO stage and the WHO stage 
defining illness at baseline, prior ARV exposure and/or history of tuberculosis or 
hepatitis, ARV drug information (the type of regimen and any substitutions within the 
regimen, duration of each ARV drug, time off ARV therapy), and immuno-virologic 
parameters (baseline and 6 monthly CD4 T-cel1 counts and HIV viral loads). Baseline 
and follow-up weights and laboratory results (CD4 counts, viral loads, lactates, pH, 
standard venous bicarbonate, alanine transaminase (AL T), haemoglobin (Hb), total 
white ceH counts (WCC), absolute neutrophil counts (NCC) and creatinine,) were also 
collected. Further follow-up assessment variables included any recorded symptoms, 
concomitant diseases and/or conditions and the medications for treatment of the 
symptoms and illnesses. 
Historically, heights were not measured in adults attending public health care services. 
As past research reported body mass index (BMI) as possibly being correlated with 
SHLA, efforts were made to collect this data. After going through each participant's 
folder to collect data, a request was written on the patient's cHnical record to measure 
the patient's height at the next appointment and report the findings to the authors of 
the case-series or case-control study_ Many of the clinics were visited a second time, 
with new notes written in the patients' folders requesting height measurements. 
Logistics 
A clinician from G.F. Jooste ARV referral clinic is completing a case-series on 
patients with a diagnosis of SHLA. The names of the cases, their primary health care 
facility and their laboratory results at diagnosis were provided by the author of the 
case series. 
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6.6. Data Analysis 
Referral Rates 
The referral rate was calculated by adding up all of the patient months on ARVs at 
each of the primary health care facilities in the G.F. Jooste drainage area since the 
start of ART. The months were then divided by twelve to elicit the total patient years 
on treatment during the study period at each of the ARV health facilities. The number 
of cases referred from each site was then multiplied by 1,000, with the result then 
divided by the number of patient years at each facility, giving a referral rate by each 
clinic. The same calculation was done on the sum of all cases referred from the ARV 
services in the G. F. Jooste Hospital drainage area to result in an overall referral rate. 
A newly proposed referral rate was also determined, by following the same 
calculations above, but only counting the months from patients during their 6-18 
month duration on ARV therapy. 
Inclusion and exclusion of variables 
There were many variables that had very small numbers of observations, such as some 
symptoms, World Health Organization (WHO) stage defining illnesses and 
occasionally prescribed medications. If the event did not occur within at least 3 
participants, it was not analysed. 
Defining measurements of non-numerical data 
True categorical data (sex, exposure to the Prevention of Mother To Child 
Transmission [PMTCT] programme and WHO stage) were left in their natural 
categories during analysis. WHO stage defining illnesses were also naturally grouped 
as a binary variable, as these illnesses were recorded for eligibility and staging criteria 
if the patient had ever experienced them during the work-up appointments prior to 
initiating ARV therapy. All cases had been exposed to d4T for several months, 
providing no variance in the cases when treating d4T as a binary variable, exposed 
and unexposed. As duration on AR V therapy was also matched, according to study 
design, the only measure that would provide variance would be categorizing AR V 
drugs into a binary variable. A participant that experienced an ARV drug for 100 
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days or more (the first case presented after 109 days of ARV exposure) during the 
study period was considered exposed. 
Upon looking through the database at individual cases, symptoms which were 
repeated at adjacent visits prior to case presentation were carefully traced back to 
detennine that a cut-off of 80 days prior to case diagnosis would pick up most if not 
all symptoms possibly related to SHLA. As different health facilities had different 
management protocols, including different lengths of time between clinical 
consultations (from 1 to 4 months), counting the number of complaints per symptom 
per patient could potentially bias the study (as each clinic contributed a different 
number of cases). A systematic detennination for the duration of a symptom also 
could not be assessed due to the different lengths of time between scheduled 
appointments (applying half the time between consultations to a symptom that was 
not complained about from one appointment to the next would be biased depending 
on the length of time between appointments). Breaking symptom data into a binary 
variable, ever having complained of the symptom at an appointment during the 80 
days prior to the index date, seemed to be the most judicial way of detennining 
association with SHLA. However, the median time from appearance of each 
symptom to case diagnosis was further looked into when exploring the data. 
The preferable way to categorize the prescribed medications (other than ARV drugs) 
would have also been according to duration of exposure. Upon closer inspection of 
the data, many of the prescribed drugs did not have further detail other than the name 
of the drug and date prescribed. Without stop dates, number of pills, or length of days 
for the prescription, exposure duration could not be detennined. The medications 
were also grouped into binary categories as well, exposure being determined if the 
participant ever received the medication within the 80 days prior to the case diagnosis. 
Exploratory analysis 
The data was analysed using STATATM (Version 10, College Station, TX, USA). 
Categorical data was described using frequencies and proportions. The nature of the 
distribution of the continuous variables was detennined using the Shapiro-Wilk test 
for nonnality. Normally distributed continuous variables were reported using 
frequencies and means. Non-nonnally distributed continuous variables were 
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described using frequencies and medians. It was expected that some of the variables 
may be highly correlated with each other. To examine potential multicollinearity, the 
relationships between variables were examined using correlation coefficients. For 
normally distributed continuous variables, the Pearson Correlation Coefficient was 
calculated, while the Spearman Rank Correlation Coefficient was determined for 
variables with skewed distributions. 
Groupings within variables 
All symptoms and medications were looked at in univariate analysis to detect any 
possible new signals. Due to the small numbers of patients experiencing a particular 
symptom or ingesting a particular prescribed drug, it was decided to categorize within 
these variables in order to increase statistical power. Symptoms of SHLA were 
grouped according to literature. The symptoms that were repeatedly described as 
correlated with SHLA in all articles describing symptoms for this condition formed 
the group called major symptoms, while symptoms that were sporadically reported in 
articles formed the minor symptoms category. 
Univariate regression models 
The variables and their relationship with SHLA were first described univariately in 
crude form using a conditional logistic regression. All explanatory variables that were 
found to be associated with SHLA in the univariate analysis were included in the 
model building steps for the multivariate analysis, with the exception of the 
occasional medications, height and body mass index. 
The occasional medications were found to be highly correlated to the symptoms 
during exploratory analysis and were therefore not chosen to be in the full models. 
Measurements for height and body mass index were also dropped from the full 
models due to the very small numbers of participants having this data. 
Multivariate model building procedure 
A systematic model building process was used in determining the final full models. 
First, a priori confounders were entered into the conditional logistic regression model, 
one at a time. For those confounders that were collinear, the strongest variable was 
chosen (largest chi2 ratio). Interactions between the confounders were then looked at. 
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A newly generated interaction variable was kept in the model if there was enough 
evidence (the confidence interval did not cross the null) to support the fact that the 
interaction variable impacted on the model. The next step was to add the variables 
found during univariate conditional regression analysis to be associated with SHLA, 
one at a time. The best model (the one with the lowest Akaike's information criterion 
(AIC) and Bayesian information criterion (SIC) number (ifthe compared models 
were close in terms of the AIC and BIC, then the one keeping the most observations» 
was chosen each time. Then the process of adding one variable at a time was started 
again with all of the remaining variables. This systematic process was stopped when 
the model became unstable due to the small cells, or when the addition of another 
variable did not seem to make an impact on the model (the AIC or BIC number did 
not numerically decrease). 
Once all variables that impacted the model were built into it, interactions between all 
variables in the final model were looked at. Interactions between all the variables 
were tested one at a time within the model to see if any newly generated interactions 
had enough evidence to support association with SHLA. If there was an association 
found, the interaction variable was kept in the model. Variables were placed back 
into the model at this point (if the were removed due to small cells) and interactions 
variables were generated one at a time with each ofthe variables left in the model to 
see if the decision for their exclusion was premature. None of the variables removed 
contributed to an interaction variable that had an association with SHLA. As there 
was little impact on other variables with inclusion of the significant interaction 
variables, and their inclusion highly magnified the odds ratios, the inclusion variables 
were dropped. Please see appendix I for a close look at the model building process. 
Different multivariate models 
The above described model building process was used to build 3 multivariate 
conditional logistic regression models. The first model was built to describe risk 
factors at baseline and the first few months on ARV therapy. As there are fewer 
variables involved, the data describing the sex, age and baseline CD4 count could stay 
in the model without creating too much instability. It was deemed necessary to have a 
model that would not only describe these important variables that often fell out of the 
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more complex models, but also to emphasize risk factors that could be managed in a 
preventative way during the time of initiating patients onto ARV therapy. 
The second model, which was the first to include data recorded during follow-up 
appointments, quickly became very unstable after inclusion of the very strong variable 
called AL T gain, which described the difference in ALT from baseline to peak values. 
The numbers of participants having this measurement was small, resulting in the 
exclusion of over 100 patients whose matched group did not have at least one case 
and control with this measurement taken. The result of dropping so many patients 
was an unstable model that could not hold additional variables. This model has been 
fully reported in the results. 
The third model was built for variables explored during follow-up. As described 
above in the model building process, some of the variables were removed from the 
model due to small numbers in some cells during regression resulting in a model too 
complex to compute correctly. 
A further two models were built using data from the cases only. As the cases were no 
longer matched, logistic regression was used instead of a conditional logistic 
regression. The fourth model attempted to describe variables associated with the 
severity of this condition, namely an outcome of SH versus an outcome of LA. A 
fifth and last model was built to describe factors associated with acute death after 
diagnosis of SH or LA. Both the fourth and fifth models considered variables found 
upon case diagnosis at G.F. Jooste Secondary Referral clinic (laboratory tests) and 
variables that were in the above described multivariate models. 
After all models were decided upon for their best fit, the numeric variables were 
broken into categories for easier interpretation when sensible, as long as the model 
remained stable. 
Model Checking 
The models were assessed for fit using the diagnostics for a matched one-to-many 
conditional logistic regression. However, further than fit, there is no definitive way to 
check the diagnostics of a model in a one-to-many matched case control, so it was 
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decided to break each pair of controls into two separate groups, and combine each 
group separately with the data for the cases. This will result in two separate models of 
one-to-one conditional logistic regressions, allowing for further diagnostics. 
7. Ethics: 
The protocol was submitted to the Research Ethics Committee of the University of 
Cape Town Health Sciences Faculty for review. Confidentiality was ensured and 
practiced at all times. 
Although this study was not being funded by the Provincial Department of Health, the 
author was working with them as the assistant director of monitoring and evaluation 
of the ARV programme. As per job requirement, and under strict obligations to 
confidentiality, the author had access to all ARV registers and patients' folders at the 
public ARV dedicated facilities across the Western Cape. However, information 
accessed for purposes of this study was with approval from the Ethics Committee, the 
five named ARV facilities, and under supervision by the sites' clinicians. 
All information linked to unique identifiers, such as names and folder numbers was 
kept solely by the authors of the case series, my supervisor, and the author ofthis 
study. Written reports will only contain aggregated numbers. 
As this study was a review of records, no invasive techniques or direct contact with 
the patient was required during collection of the data. Therefore, no foreseeable harm 
to the individual patient was perceived during data collection. The results of the study 
may heighten fear of adverse events surrounding ARV therapy, however, emphasis 
has been placed on the fact that SHLA is a rare condition. 
The information elicited from this study should greatly outweigh any harm to the 
individual or community studied. This study was approved without the requirement 
of informed consent, as per discussions held with the ethics committee on enhanced 
routine monitoring. 
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It is anticipated that results from this study will benefit the studied population, as 
possible risk factors and clinical features of SHLA in the South African context are 
more clearly defined. 
Reporting of results 
The results of the study will be made available in a written report to all clinicians at 
the ARV dedicated sites, all referral hospitals, the department of health and other 
interested parties. The study will be forwarded to reputable journals in hope of 
publication. 
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8. Results 
8.1. Descriptive Statistics 
8.1.1. Partic.ipants 
Cases 
Eighty-six patients were referred to the G. F. Jooste Secondary Referral Clinic with a 
lactate ~ 5 mmolll between 1 August 2003 and 30 November 2005. Of the 86 
patients, 13 were excluded from the study as they had SHLA attributable to causes 
other than ARV therapy. Of the 13 excluded patients, 4 were not on HAART, 4 had 
severe hypoxia, hepatitis or dehydration as likely causes and 5 had norrnallactates on 
repeated tests signifying possible spurious results. As access to the primary health 
care folders of two cases was not obtainable, this study includes 71 cases ofSHLA 
(Figure 1). 
Controls 
For increased statistical power, two controls were matched to every case by facility 
and AR V commencement month. Therefore, altogether there are 142 randomly 
sampled controls consisting of 138 patients of which 4 are sampled twice. As there 
were few patients commencing ART per clinic when anti-retroviral medication first 
became publicly available, the number of available patients that fit the inclusion 
criteria was limited in early cohorts causing 4 repetitions in controls. 
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Table 1: Primary Health Care Referral Clinics 
Clinic Cases Controls Percent 
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8.1.3. Duration on ARV therapy prior to case diagnosis 
Cases were on ARV therapy for a median duration of 10 months (IQR: 8.5 - 11.8) 
prior to presenting at the G.F. Jooste Secondary Referral Clinic. All 71 cases 
presented at some point between 3.5 and 31 months on ARV therapy, with the 
distribution being slightly skewed to the right. Ninety-five percent of the cases 
presented between 6.5 months and 17.1 months on AR V therapy. 
Some of the outliers presenting after longer durations of ARV therapy are due to the 
patients being on AZT prior to substitution with d4T. The 2 cases presenting at 30 
months both started on AZT, one for 10 months and one for 13 months, prior to AZT 
being substituted with d4T. The case which presented at 26 months was on d4T 60mg 
per day for 10 months prior to the dosage being switched to d4T 80mg per day, while 
the case presenting at 17 months was on d4T 60mg for five months prior to d4T 
80mg. The case which presented at 16 months was on AZT for 4 months prior to the 
NRTI being substituted with d4T 80mg (Figure 2). 
Results> Descriptive Statistics 26 
" 
" ! " • 
" " ,




• 51 I . ~ ~ O ~ N~~~~~~~ O~ Nn~ ~~~.~ O_N~ .~ ~~~ ~O ~ _ _ ___ _ ___ NN NNNNNNN ~ 
Montl!s 
K IA. Ad ult elise n.'r('rr~ 1 rloI l l' 
'''erc we~ 13 SI ILA cas~ Idemls 10 1M G.F. JOOSt" Sc'(:onda.r) RefmaJ Clink 
during Ihe study period, "i1h 67 ~r~mtls coming from lJKo pnmary ""all" care c("mrell 
in thcir drainugc ~a. 
The iat}!1."S1 nlli nbcr of n:fcrmls (n'" IS) from a cl inic in the rc fclTIl l area ~~mc fmm 
Sire B CHe. in the Kha)cliislut Jub-d istricl. 13 referra ls cam,' from bOll! MII(hc ll ') 
Plain CHe and G,F. JOO5le In(<<liOIl! Disease Chnic. 10 from lh ~ Gu~u lelh\l CIIC 
and 6 from Cnmroods CIIC. l1o .... e\cr. Crossroad, tIad lhe hisheS! OH~rnll referral 
111'" (36 po:r 1,000 pJllcm ~"eal'$) and Guguli:thu CIIC 1\1l1ungilc CIIC and Site B 
CIIC had the 1_ HI It'fcrrtl l niles (9. 1. 9.1 an.! 9.5 cases po:r 1,000 palient y~~rs on 
treatment. n.'5pcc li, el) J. With the cxccptioo of G.F. JOOSk I lospita i. the n:fl!'mll rates 
ltl.ok.! 10 incrcllSl: in accOi"tbnc:c to the ~\lIn d:atc of the AM. V SCl'\'IC.., al each of the 
hcahh fndl hiC$, \\ ilh more mature services referring moll: (1I5CS pcr ""Iienl load, 1lle 
0' cl'IIl1 rd..,ml rn le, " h.'" c<>"sidering all ratienls on ARV thCl'/lp)' during ~ $Ioor 
pcriod, WIIS I J.~ (II5C' of SHLA r-:r 1000 patient }cal'5 on treatmenl (labl" 2). 
!\;ncl} -f"" pc~enl of Ihe ellSCS wen: diagllOSed bo:t" cen 6- 1 H months Ull AM. V 
thf:rapy. 'The nev.ly proposed referral rntc onl}' Ntlnb the months conlributed by 
patients dum>g Iheir 6 10 1 R month dl.Ll'/l1ion on AM. V thC1'llp)' durinJ; the 5tuJ) p;,riod. 
" 
The overall newly calculated referral rate was 32.1 SHLA cases and 16.8 LA cases 
per 1000 patient years at risk. Although there was still a lot of variation across the 
clinics, the referral rate for years at risk was similar among the facilities with longer. 
standing AR V services. 
Table 2: Adult case referral rate from ARV services in the G.F. Jooste referral area 
SHLA Newly 
Total Total Referral Rate proposed 
ARVservice patient patient (per 1,000 SHLA referral 
Referral clinics Start Date months years cases patient years) rate* 
Crossroads CHC Sep.2004 2,221 166.6 6 36 99.4 
Mitchell's Plain CHC Mar. 2004 7,751 581.3 13 22.4 41.7 
G. F. Jooste Hospital Oct. 2003 5,529 414.7 I3 31.3 60.0 
Guguletu CHC Sep.2002 14,662 1099.7 10 9.1 20.9 
Nolungile CHC May 2001 14,702 1l02.7 10 9.1 27.0 
Site B, KhayeIitsha CHC May 2001 21,085 1581.4 15 9.5 23.2 
Total 65,950 4946.3 67 il~ ]I.1 
Lactic acidosis referral rate :: 35 7.1 16.8 
*based on all patients with 6-18 months duration on ART durlng study perlod 
8.1.5. Baseline Characteristics 
Demographic and clinical characteristics 
The age of the participants did not vary greatly between the studied groups, with the 
median age for cases being 36 years old and 34 for controls (OR 0.9; 95% CI 0.8 
1.1). Ninety four percent of the cases and 96% of the controls had a baseline weight 
that was measured and recorded in their primary health care folder. Almost 75% of 
these cases had a baseline weight of65 kg or more, while only 30% of the controls 
had baseline weights 2: than 65 kg. The median baseline weight for cases was 73 kg 
and 60 kg for controls (OR 1.1; 95% ClI.O -1.1). Seventy-three percent of the 
cases' heights and only 35% of the controls' heights were reported to the author. 
Interestingly, there was a large difference in the height of the cases and controls, with 
the mean for cases being almost 5 centimetres (cm) shorter then the controls (OR 0.6 
per 5 centimetres (cm); 95% CI 0.4 - 0.9). The mean BMI for cases was 29.9 (IQR: 
28.3 - 31.5) and 24.4 for controls (IQR: 22.6 - 26.3). 
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Over 94% of the cases were female, where only 66 % of the controls were female. In 
the ARV roll-out in the public health sector of the Western Cape, 65.9% of the adult 
population is female, suggesting that the controls represent the Western Cape 
population well, at least when considering gender. None of the cases were pregnant 
when starting ARVs, but 3 of the selected controls had been referred to the ARV 
services while pregnant. Fourteen percent of the cases and 11% of the controls were 
exposed to ARVs in the past as attendees in the Prevention of Mother To Child 
Transmission (PMTCT) Programme during pregnancy (Table 3). 
Table 3: Baseline demographic and clinical characteristics of the cases and controls 
Cases Controls 
(n = 71) (n = 142) 
Pls. Median Pls. Median Crude OR p-value 95%CI 
Age, per 5 year Interval 69 34.0 142 36.3 0.9 0.277 (0.8 - 1.1) 
Weight, kg (cont) 67 73.0 136 60.0 1.1 <0.001 (1.0-1.1) 
Weight, kg (cat) Pts. Percent Pls. Percent 
<55 6 9.4 43 32.3 reference category 
55 to <60 6 9.4 23 17.3 2.1 0.246 (0.6 - 7.4) 
60 to <65 5 7.8 26 19.6 1.3 0.659 (0.4 - 4.7) 
65 to <75 20 31.3 23 17.3 5.8 0.002 (1.9 - 17.6) 
2:75 27 42.2 18 13.5 8.1 <0.001 (2.8 - 23.8) 
Pts. Mean Pls. Mean 
8MI (cont) 49 29.9 49 24.42 1.2 0.001 (1.1-1.4) 
8MI (cat) Pts. Percent Pls. Percent 
<25 9 18.4 31 63.3 reference category 
25 to <30 15 30.6 12 24.5 3.6 0.067 (0.9 - 14.2) 
2:30 25 51.0 6 12.2 28.5 0.002 (3.3 - 242.7) 
Pls. Mean Pts. Mean 
Height, per 5 cm (cont) 52 157.2 49 161.94 0.6 0.012 (0.4 - 0.9) 
Height, cm (cat) Pts. Percent Pls. Percent 
<160 36 69.2 19 38.8 reference category 
160 to <165 9 17.3 11 22.5 0.9 0.841 (0.2 - 3.2) 
2:165 7 13.5 19 38.8 0.1 0.014 «0.1 - 0.7) 
Sex Pts. Percent Pts. Percent 
Female 67 94.4 94 66.2 10.0 <0.001 (3.0 - 33.2) 
Male 4 5.6 48 33.8 reference category 
PrlorARVs 
PMTCT 10 14.1 16 11.3 1.3 0.572 (0.6 - 2.8) 
Pregnant 
Yes 0 0.0 3 2.1 can't comeute !eaud~ of cases) 
Note: Patients (Pfs); continuous (cont); categories (cat) 
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Baseline laboratory results 
There were not any baseline laboratory tests measured in this study which were found 
to be associated with SHLA during crude analysis. The median CD4 nadir cell count 
for cases was 90 cells/mm3, while for controls the median was just over 100 cells/mm3 
(OR 0.8 per 100 cells/mm3; 95% CI 0.5 - 1.2). The median alanine transaminase 
(ALT) levels (median = 24), haemoglobin levels (median = 11) and neutrophil levels 
(median= 2) were the same for cases and controls. Baseline creatinine levels (OR 0.8 
per 10 mmollL increase; 95% CI 0.7 -1.3) and total white cell counts (OR = 0.7 per 
10 cells/mm3; 95% CI 0.1 -7.8) were also comparable between cases and controls 
(Table 4). 
Table 4: Baseline laboratory results 
Casas In. 71) Controls In • 142) 
Pts Median Pis Median Crude OR p-vslue 95%CI 
C04 count, per 100 cellslmm3 65 90 129 101 0.8 0.298 (0.5 -1.2} 
Viral load count, per 100,000 copieslmL 60 110,000 114 97,519 1.0 0.340 (1.0-1.1} 
ALT, per 10 U/L 52 24 93 24 0.8 0.298 (0.8-1.1} 
Hemoglobin, per 10 g/dL 49 11 94 11 0.9 0.855 (0.3 - 2.6} 
Creatinine, per 10 mmollL 10 67 21 61 0.8 0.548 (0.6 - 1.2) 
Nueutrophil count, cellslmm3 34 2 58 2 0.9 0.715 (0.7 -1.3} 
Tolal white cell count, per 10 cellslmm3 48 4 83 5 0.7 0.775 (0.1 - 7.8) 
Note: The ORs refer to the odds of being a case per unit increase 
WHO stages and the stage defining illnesses 
Seventy of the 71 cases and 141 of 142 controls had a stage defining illness or WHO 
stage recorded in their primary health folder at baseline. The percentage of cases and 
controls were comparable for all stages. About 35% of the participants had a stage IV 
defining illness, 50% had a stage III defining illness, and 15% had a stage I or II 
defining illness upon commencement of ARV therapy. There are relatively the same 
percentages of cases and controls if one compares the WHO stages to the CD4 count 
categories, with about 30% of cases and controls beginning ARV therapy with CD4 
counts less than 50 and about 45% with CD4 counts less than 150 cells/mm3• Cases 
with SHLA were not found to be at greater odds of having a chronic medical 
condition prior to commencing ARV therapy (Table 5). 
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Table 5: WHO stage defining illnesses, WHO stages, CD4 count categories and medical 
conditions 
Cases Controls 
(n = 71) (n = 142) 
Pis Percent PIs Percent Crude OR p-value 95%CI 
WHO stage defining Illness 
Diarrhoea> 1 month 2 2.8 10 7.0 0.3 0.196 (0.1 - 1.7) 
Oral Candidiasis 30 42.3 50 35.2 1.4 0.312 (0.7 - 2.5) 
Oral hairy leukoplakia 7 9.9 8 5.6 1.8 0.264 (0.6 - 5.3) 
TuberculosiS 30 42.2 58 40.1 1.1 0.850 (0.6 - 1.8) 
Oesophageal candidiasis 8 11.3 10 7.0 1.7 0.288 (0.6 - 4.8) 
Pneumocystis carinii pneumonia 4 5.6 5 3.5 1.7 0.458 (0.4 -7.0) 
HIV wasting syndrome 1 1.4 4 2.8 0.4 0.489 (0.0 - 4.6) 
HIV encephalopathy 1 1.4 2 1.4 1.0 1.000 (0.1 -11.0) 
Cryptococcal MeningitiS 4 5.6 1 0.7 8.0 0.063 (0.9 - 71.6) 
Cervical cancer 3 4.2 0 0.0 can't compute (paucity of controls) 
Kaposis sarcoma 0 0.0 5 3.5 can't compute (paucity of cases) 
Immune thrombocytopenia purpura 1 1.4 4 2.8 0.5 0.535 (0.1 - 4.5) 
WHO stage 
I 3 4.3 7 5.0 reference category 
II 8 11.4 14 9.9 1.2 0.852 (0.3 4.9) 
III 34 48.6 71 50.4 1.0 0.949 (0.3 - 3.3) 
IV 25 35.7 49 34.8 1.0 0.974 (0.3 - 3.7) 
CD4 count, cellslmm3 Pts Percent PIs Percent 
<25 13 20.3 20 15.6 reference category 
25t049 6 9.4 17 13.3 0.4 0.189 (0.1 - 1.5) 
50 to 99 16 25.0 29 22.7 0.8 0.565 (0.3 - 2.0) 
100 to 149 13 20.3 29 22.7 0.6 0.340 (0.2-1.7) 
O!:150 16 25.0 33 25.8 0.7 0.496 (0.3 - 1.8) 
Medical conditions 
Diabetes 3 4.2 2 1.4 3.0 0.229 (0.5 - 18.0) 
Hypertension 4 5.6 1 0.7 8.0 0.063 (0.9 - 71.6) 
Pregnant 2 2.8 9 6.3 0.4 0.277 (0.1 - 2.0) 
Epilepsy 2 2.8 2 1.4 2.7 0.429 (0.2 - 33.0) 
Note: Patients (Pfs) 
8.1.6. Characteristics of PHC follow-up period 
Anti-retroviral drugs 
One hundred percent of the cases were exposed to d4T for 2: 100 days during therapy, 
while not one d4T naIve patient presented with SHLA to G.F. Jooste Hospital during 
the 27 month study period. The few cases that were not on d4T at the time of 
presentation had recently been switched from d4T. Eighty-seven percent (n = 124) of 
the controls had experienced d4T for 2: 100 days during the study period. Just over 
11 % (n 8) of the cases and 39% (n 56) of the controls experienced 2: 100 days of 
d4T at a dosage of 30 milligrams (mg) twice a day (crude OR 0.1; 95% CI 0.0 - 0.4). 
Ninety four percent of the controls (n = 67) and 57% (n = 81) of the cases experienced 
d4T at a dosage of 40 mg twice a day (OR 10.8; 95% CI 3.8 - 30.8). By adding the 
percentage of patients whom experienced the two different dosages of d4T together, 
by group (cases and controls separately), one can see that they each add up to more 
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than 100%. According to the Western Cape protocol, a patient below 60 kg is given a 
dosage of 60 mg of d4T per day, whiJe those over 60 kg are given 80 mg of d4T per 
day. Seven of the cases, and 31 of the controls had weights that crossed over the 60 
kg threshold during the study period resulting in the patients experiencing both 
dosages of d4T. Only 4 cases and 13 controls received both doses for ~ 100 days. Just 
over 4% (n = 3) of the cases received ~ 100 days of AZT before being exposed to d4T 
(pJease see Figures 3 and 4 for reasons leading to drug substitutions). Seventy percent 
of the cases and the controls (n = 50, n = 98 respectively) were on EFV for ~ 100 days 
(OR 1.1; 95% CI 0.5 - 2.2). Thirty one percent (n = 22) of the cases and aJmost 27% 
(n = 38) of the controls experienced ~ 100 days exposure to NVP (OR 1.3; 95% CI 
0.6 - 2.8). As all patients experienced 3TC, this drug did not enter into anaJyses. 
There were no other ARV drugs that were experienced by a patient for ~ 100 days 
during the study (TabJe 6). 
Table 6: Exposure to ARV drugs (or 100 days or greater 
d4T (60 and 80 mg) per day 
d4T 60 mg per day 






















Note: Patients (pts); a/l drugs are calculated as binary variables 
Crude OR Median 95% CI 
can't compute (all cases on d4t) 
0.1 <0.001 (0.0 - 0.4) 
10.8 <0.001 (3.8 - 30.8) 
0.1 0.052 (0.0 - 1.0) 
1.1 0.808 (0.5 - 2.2) 
1.3 0.454 (0.6 - 2.8) 
Weight gain and loss during follow-up appointments 
According to exploratory analysis, cases gained ~ 6 kg more rapidly compared to 
controls. The difference in weight gain during the first three months on ARV therapy 
ranged from a loss of9 kg to a gain of22 kg amongst both the cases and controls. 
Almost 40% of the cases, compared with just over 25% of the controls, gained more 
than 6 kg in the first 3 months on ARV therapy (OR 3.5; 95% ClI.O 12.0). Almost 
75% of the cases and 57% of the controls gained 3 or more kg during the same time 
period. 
Cases also experienced a greater loss of weight during the last 3 months prior to the 
matched case presentation date (OR 1.4; 95%CI 1.2 - 1.6). The median weight lost 
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for cases, during this time period, was 5 kg (IQR: 2 to 9), and for controls the median 
was 0 kg (IQR: -2 to 2). Over 70% of the cases (n = 45) and 17% of the controls (n = 
22) lost more than 3 kg in the 3 months prior to case diagnosis (OR 9.7; 95% CI 4.27 
- 21.85). Thirty-six percent of the cases compared to 4% of the controls lost more 
than 6 kg during this same time period (OR 52.52; 95% CI 9.83 - 280.65). Please see 
Table 7. 
Table 7: Weight gain during the first three months on ARV therapy, and weight lost during the 3 
months prior to case diagnosis 
Cases Controls 
(n = 71) (n = 142) 
Pts Median Pts Median Crude OR p-value 95%CI 
Weight gain (cont) 65 4 131 3 l.l 0.074 (0.9* - l.l) 
Pts Percent Pts Percent 
~ kg weight gain no 40 61.54 98 74.81 reference category 
yes 25 38.46 33 25.19 1.8 0.067 (0.9* - 3.5) 
Weight gain (cat) <0 6 9.23 24 18.32 reference category 
o to <3 11 16.92 32 24.43 1.6 0.504 (0.4 - 6.2) 
3 to <6 23 35.38 42 32.06 2.6 0.119 (0.8 - 8.4) 
~6 25 38.46 33 25.19 3.5 0.045 (1.0 - 12.0) 
Pts Median Pts Median 
Weight loss (cont) 64 5 126 0 1.4 <0.001 (1.2 - 1.6) 
Pts Percent Pts Percent 
~ kg weight loss no 19 29.7 104 82.5 reference category 
yes 45 70.3 22 17.5 9.7 <0.001 (4.3 - 21.8) 
Weight loss <0 10 16.4 44 43.6 reference category 
Oto<3 12 19.7 39 38.6 2.7 0.160 (0.7 - 10.8) 
3 to <6 17 27.9 14 13.9 9.2 0.003 (2.2 - 38.6) 
~6 22 36.1 4 4.0 52.5 <0.001 (9.8 - 280.6) 
Note: Patients (Pts); the • stands/or >0.9, not rounded to show presence 0/ overlap with the null; weight 
gain data is from baseline to 3 months on therapy; weight loss data is from last three months prior 
to case diagnosis 
laboratory Tests during follow up anvointments 
The median CD4 count at 6 months was 195 cells/mm3 for cases, with the median 
gain from baseline to 6 months of 107 cells/mm3 in the same group. Controls had a 
median CD4 count of 122 cells/mm3 at 6 months, with a median 126 cells/mm3 gain 
between baseline and six months. During crude analysis, it was found that cases 
tended to have lower CD4 counts at 6 months when compared to controls (OR 0.9 per 
50 cell/mm3 increase; 95% CI 0.8 - 0.9). However, the gain in CD4 count from 
baseline to 6 months was not found to be associated with case status (OR 0.9 per 50 
cell/mm3 increase; 95% CI 0.9 - 1.1). The Spearman Correlation Coefficient showed 
Results> Descriptive Statistics 33 
that the CD4 count at baseline and 6 months is highly correlated with one another. 
Six cases and 7 controls had not suppressed their viral load by 6 months on therapy 
(OR 1.1; 95% CI 0.9 - 1.2). The difference in median AL T units gained from 
baseline to peak values between the cases (median = 20 UIL) and controls (median = 
5.5 UIL) was significant (OR 1.1 per 10 UIL increase; 95% ClI.O - 1.3). Over 70% 
(n = 35) of the cases and 35% (n = 30) of the controls gained at least 10 UIL of ALT 
from baseline to peak values reached during the study period. The difference (or 
gain) between baseline and peak values for hemoglobin, absolute neutrophil count, 
and total white cell count were comparable between cases and controls (Table 8). 
Table 8: Comparisons of the follow-up laboratory results between cases and controls 
Cases Controls 
(n = 71) (n = 142) 
Oinical panmeten during follow-up PIs Median PIs Median crude OR £-vaIue 95%C[ 
CD4 count at 6 months,per 50 cellslmm3 65 195.0 122 239 0.9 0.049 (0.8 - 0.9*) 
CD4 gain (nadir to 6 months), per 50 cellslmm3 61 107.0 117 126.0 0.9 0.171 (0.9 - 1.1) 
Viral load > 400 at 6 months, pr 50 copieslmL 6 9.1 7 5.6 LI 0.366 (0.9 - 1.2) 
Hemoglobin gain (baseline and peak), per 5 gldL 41 2.0 79 1.0 1.2 0.717 (0.4·3.4) 
NCC gain (baseline and peak), per 10 cellslmm3 27 1.0 48 0.0 0.9 0.872 (0.3 - 2.5) 
WCC gain (baseline and peak), cells/mm3 40 1.0 75 1.0 LI 0.584 (0.9. 1.3) 
ALT gain (baseline and peak), per 10 UIL 47 20.0 84 5.5 1.1 0.019 (1.0 - 1.3) 
ALT gain, UIL (baseline and peak, cat) PIs Percent PIs Percent 
<0 3 6.4 18 21.4 reference categolj' 
o to <10 9 19.2 36 42.9 1.2 0.856 (0.3.5.3) 
1010<20 II 23.4 12 14.3 6.1 0.024 (1.3 • 28.9) 
2:20 24 51.1 18 21.4 6.7 0.010 (1.6 - 28.5) 
PIs Median PIs Median 
ALT gain, UlL (baseline and last 80 days) 39 51.0 39 51.0 1.1 0.118 (0.9* -1.2) 
AL T gain, UIL (baseline and last 80 days, cat) PIs Percent PIs Percent 
<0 3 11.5 12 41.38 reference category 
o to <10 3 11.5 7 24.14 1.4 0.830 (0.1 ·28.6) 
10 to <20 6 23.1 5 17.24 5.0 0.227 (0.4·68.7) 
>20 14 53.8 5 17.24 1Q.6 0.144 ~O.4 - 252.4~ 
Note: the * means> 0.9, but did not round to show the presence or absence of crossing the null; categories (cat): 
patients (pts) 
Symptoms reported during 80 days prior to case diagnosis 
Table 9 describes the number of patients ever reporting a particular symptom during 
the 80 days prior to case presentation. Only those symptoms that had a frequency of 
>3 are reported below. The symptoms most strongly associated (OR ~ 8) with SHLA 
include chest pain (OR 8.3; 95% CI 1.8 - 38.7), abdominal pain (OR 13.5; 95% CI 
4.7 38.9), nausea (OR 8.0; 95% CI 2.3 28.3), poor appetite (OR 19.3; 95% CI 4.5 
- 82.6) and vomiting (OR 30.0; 95% CI 7.0 - 128.1). However, back pain, general 
body pain, weakness, facial and limb swelling, flu-like symptoms, itching eyes and 
cough were also positively associated with SHLA. Conclusive evidence to support 
the association between diarrhoea and SHLA were borderline (OR 3.1; 95% CI 0.9 
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9.7). There was no association found between SHLA and symptoms ofrash, 
headaches, insomnia or sexually transmitted diseases. Odds ratios cannot be reported 
for those complaining of being tired or experiencing heartburn due to a lack of 
controls reporting the same symptoms. 
Symptoms related to the lipodystrophy and peripheral neuropathy were also strongly 
associated with SHLA. Patients with SHLA were found to have a 6-fold increased 
odds for symptoms oflipoatrophy or lipohypertrophy (95% CI 1.6 - 22.2), while 
those with SHLA were 6.4 times (95% CI 2.9 - 14.3) more likely to suffer from 
symptoms related to peripheral neuropathy. Concomitant pulmonary tuberculosis 
during ARV treatment was not shown to be correlated with SHLA. 
The symptoms affecting the most people, a combination of cases and controls, were 
those related to upper respiratory tract infections. Forty-six of the 213 patients (24 
cases and 22 controls) complained of having flu-like symptoms during the 80 days 
prior to diagnosis. Peripheral neuropathy affected the most cases, with 29 people 
(41 %) complaining of pins and needles, cramping and pain in their hands and feet. 
Twenty-eight cases (39%) suffered from abdominal pain and 27 cases (38%) suffered 
from vomiting. 
According to the unadjusted odds ratio, cases with SHLA were 20 times more likely 
(95% CI 7.1 - 56.6) to experience at least one of the three major SHLA symptoms 
(abdominal pain, nausea, vomiting) compared to controls during the 80 days prior to 
case presentation at G.F. Jooste Hospital. Patients with SHLA were 6.2 times more 
likely (95% CI 3.0 12.5) to have suffered from at least one of the minor symptoms 
related to SHLA in the 80 day time period prior to case diagnosis. Minor SHL 
symptoms include chest pain, cough, diarrhoea, generalised body pain, shortness of 
breath and fatigue. Having ever had an HIV correlated infectious disease in the same 
time period was not found to be associated with SHLA, nor was ever having a 
concomitant non-SHLA associated co-morbidity (arthritis, cancer, hypertension, 
epilepsy, diabetes, guilliane barre or Steven-Johnsons syndrome). 
Cases were more likely to experience a combination of symptoms when compared to 
controls. Cases had a median of 4 symptoms (IQR 1-6) associated with SHLA in the 
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80 days prior to case diagnosis, while controls had a median of 0 symptoms (IQR 0-1) 
during that same time period (OR 2.0 per each additional symptom; 95% CI 1.5 -
2.6). 
Table 9: Number of patients reporting symptoms in 80 days prior to case diagnosis 
Cases (n = 71) Controls (n = 142) 
Body as a whole Pts Percent PIs Percent Crude OR e-value 95% CI 
back pain 8 11.3 3 2.1 5.3 0.013 (1.4-20.1) 
chest pain 9 12.7 3 2.1 8.3 0.007 (1.8 - 38.7) 
general body pain 10 14.1 3 2.1 7.2 0.003 (1.9 - 26.8) 
tired 8 11.3 0 0.0 can't compute (lack of controls) 
weakness 6 8.5 3 2.1 4.0 0.050 (1.0 - 16.0) 
facial or 11mb swelling 12 16.9 5 3.5 4.8 0.003 (1.7 - 13.6) 
flu-like symptoms 24 33.8 22 15.5 2.8 0.003 (1.3 - 5.4) 
itching eyes 8 11.3 5 3.5 4.4 0.030 (1.2-17.1) 
rash 11 15.5 20 14.1 1.1 0.777 (0.5 - 2.6) 
headache 9 12.7 13 9.2 1.5 0.420 (0.6 - 3.7) 
insomnia 1 1.4 3 2.1 0.7 0.725 (0.1 - 6.4) 
Digestive 
abdominal pain 28 39.4 7 4.9 13.5 <0.001 (4.7 - 38.9) 
nausea 12 16.9 3 2.1 8.0 0.001 (2.3 - 28.3) 
poor appetite 21 29.6 5 3.5 19.3 <0.001 (4.5 - 82.6) 
vomiting 27 38.0 2 1.4 30.0 <0.001 (7.0 - 128.1) 
heartburn 10 14.1 1 0.7 can't compute (lack of controls) 
diarrhoea 8 11.3 6 4.2 3.1 0.057 (0.9* - 9.7) 
Respiratory 
cough 21 29.6 19 13.4 2.8 0.006 (1.4 - 5.8) 
shortness of breath 8 11.3 2 1.4 8.0 0.009 (1.7 - 37.67) 
Genital Tract 
sexually transmitted disease 4 5.6 4 2.8 1.7 0.384 (0.5 - 6.1) 
Comorbldltles 
lipodystrophy 9 12.7 3 2.1 6.0 0.007 (1.6 - 22.2) 
peripheral neuropathy 29 40.9 14 9.9 6.4 <0.001 (2.9 - 14.3) 
tuberculosis - pulmonary 3 4.2 4 2.8 1.5 0.596 (0.3 - 6.7) 
Categories 
Major SHLA symptoms 41 57.8 9 6.3 20.0 <0.001 (7.1 - 56.6) 
Minor SHLA symptoms 42 59.2 28 19.7 6.2 <0.001 (3.0 -12.5) 
HIV related illness 12 16.9 16 11.3 1.6 0.243 (0.7 - 3.8) 
Comorbidlties 15 21.1 13 9.2 1.5 0.436 (0.5 - 4.7) 
Median IQR Median JQR crude OR e-value 95%CI 
Combination of symptoms 
Number of s~metoms 4 11-6! 0 0-1 2.0 <0.001 
Note: Patients (Pts); the * stands for >0.9, not rounded to show presence of overlap with the null; 
(1.5 - 2.6) 
OR for 'number of symptoms' Is per each additional symptom 
In an attempt to better describe symptoms experienced by patients before diagnosis 
with SHLA, the median delay, in days, between the symptom first appearing and case 
diagnosis was determined. The time period to look at symptoms was restricted to the 
last 80 days prior to case diagnosis, as this interval was felt wide enough to be 
sensitive, yet short enough to exclude as many of the non-SHL symptoms as possible. 
This exploration was also limited to cases. 
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The analysis showed that back pain (median delay =47 days; IQR=33-67), chest pain 
(median delay =44 days; IQR 8-57) and itching or red eyes (median delay =37 days; 
IQR=16-66) had onsets that were most distant from case presentation. Fatigue 
(median duration =8 days), shortness of breath (median duration =11 days), nausea 
(median duration =12 days), generalized body pain (median duration =12 days), and 
poor appetite (median duration =14 days) seem to manifest closer to the time of case 
presentation (Table 10). 
Table 10: Median delay from first presentation of symptom to case diagnosis (in 80 days prior to 
case presentation) 
Cases (n = 71) 
Body as a whole Obs median duration IQR 
back pain 8 47 (33-67) 
chest pain 9 44 (8-57) 
general body pain 10 12 (1-30) 
tired 8 8 (6-23) 
weakness 6 21 (3-40) 
facial or limb swelling 12 23 (11-50) 
itching eyes 8 37 (16-66) 
Digestive 
abdominal pain 28 22 (6-38) 
nausea 12 12 (4-21 ) 
poor appeti te 21 14 ( 1-44) 
vomiting 27 21 (3-42) 
heartburn 10 21 (7-25) 
Respiratory 
shortness of breath \I (3-25) 
Comorbidities 
lipodystrophy 9 17 (4-24) 
peripheral neuropathy 29 27 (11-50) 
Prescribed medications during 80 days prior to case diagnosis 
Drugs prescribed more than 3 times by study participants in the 80 days prior to case 
diagnosis are listed in Table 11. Hyoscine butylbromide (OR 4.3; 95% CI 1.1 -
16.5), ibuprofen (OR 6.1; 95% CI 1.9 -19.4), loperamide (OR 4.0; 95% CI 1.0 - 16.) 
and metoclopramide (OR 10.0; 95% CI 2.9 - 34.5) were all found to be correlated 
with SHLA. As there were few control patients taking seizure medications (controls 
= 1) and sennosides (controls = 0) it was not possible to present odds ratios for 
associations between prescribing these drugs and case status. 
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Some of the drugs were grouped into the following categories: known drugs that can 
aggravate the liver, non-steroidal inflammatory medications, antibiotics in pill form 
and vitamins. Patients with SHLA were 60 percent less likely to be prescribed 
vitamins (multi-vitamins, B-complex, or pyridoxine), even once, during the 80 days 
prior to case diagnosis (OR 0.4; 95% CI 0.2 - 0.8). The three other drug categories 
were not associated with SHLA. 
Table 11: Medication prescribed within the 80 days prior to case diagnosis 
Cases (n = 71) Controls (n = 142) 
Pts Percent Pts Percent Crude OR £-value 95%CI 
occasional drugs 
amitriptyline 9 12.7 5.6 2.4 0.086 (0.9 - 6.5) 
hyoscine butylromide 7 9.9 4 2.8 4.3 0.039 (1.1 - 16.5) 
ibuprofen 13 18.3 6 4.2 6.1 0.002 (\.9-19.4) 
fluconazole 3 4.2 3 2.1 2.0 0.396 (0.4 - 9.9) 
loperamide 6 8.5 3 2.1 4.0 0.050 (\.0 - 16.0) 
metoclopramide 15 21.1 3 2.1 10.0 <0.001 (2.9 - 34.5) 
panadiene 3 4.2 2 \,4 3.0 0.229 (0.5 - 17.9) 
panado 14 19.7 19 13.4 1.7 0.199 (0.8 - 3.9) 
paracetanol 5 7.0 4 2.8 4.0 0.109 (0.7-21.8) 
promethazine 2 2.8 3 2.1 1.3 0.753 (0.2 - 8.0) 
pyridoxine 3 4.2 2 \,4 4.6 0.193 (0.5 - 46.9) 
seizure medication 2 2.8 I 0.7 can't compute (lack of controls) 
sennosides 5 7.0 0 0.0 can't compute (lack of controls) 
tuberculosis regimen 3 4.2 2 1.4 3.0 0.229 (0.5 - 18.0) 
diclofenec 2 2.8 2 1.4 2.0 0.488 (0.3 - 142) 
Categories of occasional drugs 
drugs aggravating the liver 14 19.7 15 10.6 2.2 0.064 (0.9· - 5.2) 
non-steroidal anit-inflamatories 15 21.1 42 29.6 0.6 0.194 (0.3 - 1.3) 
antibiotics (excluding injected) 15 21.1 18 12.7 \.9 0.105 (0.9 - 4.3) 
vitamins·· 42 59.2 104 73.2 0.4 0.016 ~0.2 - 0.82 
Note: • greater than 0.9, not rounded to show presence or absence of overlap with null; 
- vitamins category contains pyrodoxine, multi vitamins, and B complex vitamins 
ARV Drug substitutions 12rior to case diagnosis 
Prior to the case presentation date, which also provided the end of follow-up for the 
matched controls, 11 cases and 14 controls had NRTI drugs substituted (Figure 3). 
Three of the 11 cases started on AZT and later changed to d4T with the remaining 8 
starting first on d4T. Two of the cases starting on AZT changed drugs due to 
virologic failure, and one due to an adverse event of a grade 4 anemia. Of the 8 
patients starting on d4T, 4 patients had their d4T substituted with AZT due to a raised 
lactate greater than 3.5 mmollL, 2 were changed to AZT due to a diagnosis of 
peripheral neuropathy, 1 due to a diagnosis of lipodystrophy and 1 due to pregnancy. 
All cases that had drug substitutions from d4T to AZT remained on AZT for a short 
period of time prior to case presentation (mean 10.6 days; 95% CI 4.1-17.0). 
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Figure 3: NRTI drug substitutions among the cases prior to case presentation date 

















n= 1 n 1 
Three of the 14 controls started on AZT which was later substituted to d4T with the 
remaining 11 starting first on d4T. Of the 3 starting on AZT, 2 patients were changed 
to d4T after giving birth to their child and one patients AZT was substituted with d4T 
due to a grade 4 nuetropoenia. Of the 11 starting on d4T first, 6 were changed to AZT 
due to peripheral neuropathy, 1 due to lipodystrophy, 1 due to both symptoms of 
peripheral neuropathy and lipodystrophy, and two were changed to AZT due to 
contraindication of d4T drugs with pregnancy (Figure 4). 
Figure 4: NRTI drub substitutions among the controls prior to the matched case presentation 
date 
Started with AZT 
Birth of Grade 4 
child nuetropoenia 
n 2 n=l 










n 1 n=3 
39 
8.1.7. Characteristics of cases at time of diagnosis 
Crude analysis of associations with acidosis 
Sixty of the 71 cases had both a pH and standard bicarbonate reading done at the time 
of diagnosis. Eleven cases did not have one or either of these results recorded in their 
folder, which did not allow for them to be grouped according to the severity of their 
condition (SH or lactic acidosis). Analysis of the laboratory results from the day of 
case diagnosis revealed creatinine and lactate levels to be associated with lactic 
acidosis. Patients with LA were more likely to have higher lactate levels (OR 1.4 for 
each mmollL increase; 95% CI 1.1-1.8) and raised creatinine levels (OR 1.5 per 10 
mgIL increase; 95% CI 1.00 - 2.4). Those patients diagnosed with lactic acidosis had 
3.6 times increased odds of gaining more than 6 kg during the first 3 months on ARV 
therapy in comparison to controls (95% CI 1.1 -12.1). ALT, lipase and resting 
glucose levels taken at case diagnosis do not appear to be associated with the severity 
of SHLA in this study population. 
Twelve of the 71 cases (16.9%) passed away after diagnosis with SHLA. Cases with 
lactic acidosis were 8.3 times more likely to pass away (95% CI 0.9 - 70.6) when 
compared to cases that didn't have as severe a condition (Table 12). 
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Table 12: Univariate analysis oflactic acidosis, cases only 
Lactic acidosis SHLA 
(n = 35) (n =25) 
Laboratory results at diagnosis pts median pts median crude OR p-value 95%CI 
pH 35 7.25 25 7.40 • ·part of LA definition 
standard venous bicarbonate, mmoIIL 35 14.0 25 20.0 ··part of LA definition 
base excess, mEq/L 31 -13.0 23 -5.0 ··part of LA definition 
lactate at presentation, mmoIIL 35 9.1 25 6.3 1.4 0.010 (1.1 - 1.8) 
ALT, per 30 UIL 21 48.0 15 48.0 l.l 0.631 (0.8 - 1.4) 
lipase, per 20 UIL 27 48.0 17 38.0 1.1 0.152 (0.9· - 1.2) 
resting glucose mgIL 11 7.9 4 6.5 1.3 0.283 (0.8 - 1.9) 
creatinine, per 10 mg/L 23 80.0 16 64.5 1.5 0.049 (1.0 - 2.4) 
Parameters measured during follow-up follow-up 
CD4 count at baseline, per 100 cellslmm3 35 87.0 23 101.0 l.l 0.806 (0.5 - 2.4) 
CD4 count at 6 months, per 100 cellslmm3 30 175.0 24 245.5 0.7 0.173 (0.4 - 1.2) 
ALT gain, per 10 UIL 22 14.0 20 28.0 1.1 0.263 (0.8 - l.l) 
weight at baseline, per 10 kg 34 71.5 23 78.0 0.8 0.250 (0.6 - 1.2) 
weight loss, kg (last 3 months in study) 31 5.0 23 7.0 0.9 0.287 (0.9 - 1.0) 
weight gain, kg (first 3 months on ARVs) 32 5.5 23 3.0 1.2 0.036 (1.0 - 1.3) 
age, per 10 years 34 35.9 25 33.7 0.9 0.594 (0.5 - 1.5) 
pts percent pts ~rcent 
female 33 94.3 24 96.0 0.7 0.765 (0.1 - 8.0) 
major SHLA symptoms 18 51.4 17 68.0 0.5 0.202 (0.2 - 1.4) 
peripheral neuropathy 13 37.1 9 36.0 l.l 0.928 (0.4-3.1) 
numerical variables split into categories 
creatinine <77mmoIIL 6 26.1 13 81.3 reference category 
creatinine >77mmoIlL 17 73.9 3 18.8 1.0 0.002 (1.0-1.1) 
weight gain <6kg (first 3 months on ARVs) 16 50.0 18 78.3 reference category 
weight gain ~6kg (first 3 months on ARVs) 26 50.0 5 21.7 3.6 0.038 (1.1-12.1) 
Sta tus of recovery after SHLA 
died··· 9 25.7 I 4.0 8.3 0.052 (0.9· - 70.6) 
Mortality obs median IQR ran§e 
duration in da~s from dia~osis to death 12 2.5 .5 - 18.5 0-172 
Note: • greater than 0.9. not rounded to show presence or absence of overlap with null; 
•• these variables make up the definition of LA. so were not regressed 
···2 patients died with unknown LA status 
Crude analysis of associations with mortality amongst the cases 
All together there were 12 cases that died after diagnosis with SHLA. The median 
time of death after diagnosis was 2.5 days with an inter-quartile range of 0.5 to 18.5 
days. There was one case that died 172 days after diagnosis. Unfortunately, this was 
due to post-obstetric sepsis, and most likely was not affected by the SHLA diagnosis. 
Only cases were looked at during this crude analysis of mortality. As the number of 
cases that died was relatively small, this particular analysis had limited power to 
demonstrate associations with mortality in univariate models. Variables found in 
univariate analysis to be associated with death include pH (OR <0.01; 95% CI <0.1 -
0.1), standard venous bicarbonate (OR 0.8 per unit increase ofmmollL; 95% CI 0.7-
0.9) and base excess (OR 0.9 per unit increase of mEqlL; 95% CI 0.8 - 0.9). Analysis 
of long term plus recently diagnosed diabetes in cases with SHLA and lactic acidosis 
did not appear as a risk factor for death amongst the cases (OR 2.7; 95% CI 0.2-
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323.6), however the confidence interval is wide and warrants further research (Table 
13). 
Table 13: Univariate analysis of mortality, cases only 
Died Survived event 
(n = 12) (n = 59) 
Laboratory results at diagnosis ~ts median ~ts median crude OR ~-value 95%CI 
lactate at presentation, mmol/L 12 9.3 59 6.8 1.I 0.109 (0.9* - 1.3) 
pH 10 7.2 51 7.3 <0.1 0.004 (0.0 - 0.1) 
venous standard bicarbonate, mmollL 10 10.4 50 18.0 0.8 0.003 (0.7 - 0.9) 
base excess, mEq/L 9 -18.0 46 -7.5 0.9 0.013 (0.8 - 0.9·) 
ALT, per 20 UIL 8 37.5 32 53.0 0.9 0.521 (0.7 - 1.2) 
lipase, per 100 UIL 9 69.0 39 38.0 1.1 0.243 (0.9 - 1.2) 
resting glucose, mgfL 3 12.9 12 6.9 1.2 0.214 (0.9 1.7) 
creatinine. per 30 mgfL 8 102.5 35 75.0 1.1 0.475 (0.9 - 1.3) 
Parameter, measured during follow-up follow-up 
CD4 count at baseline, per 25 cells/mm3 11 21.0 56 98.0 0.8 0.173 (0.6 - 1.1) 
CD4 count at 6 months, per 25 cells/mm3 9 168.0 56 211.0 0.9 0.382 (0.8 - \.I) 
age, per 1 0 years 11 37.4 58 33.8 I.S 0.207 (0.8 - 3.0) 
AL T gain, per 10 UIL 8 23.0 44 28.0 0.9 0.182 (0.7 - \.I) 
weight at baseline, per 10 kg 12 71.0 55 74.0 0.8 0.390 (0.5 - 1.3) 
weight loss, per 20 kg (last 3 months) 12 6.0 52 5.0 1.0 0.982 (0.1-10.1) 
weight gain, kg (first 3 months on ARVs) 11 7.0 54 4.0 1.1 0.206 (0.9· - 1.2) 
pts [!!rcent pts [!!rcent 
female 10 83.3 57 96.6 0.2 0.100 (0.0 - 1.4) 
major SHLA symptoms 6 50.0 35 59.3 0.7 0.553 (0.2 - 2.4) 
symptoms of peripheral neuropathy 3 25.0 26 44.1 0.4 0.230 (0.1 - 1.7) 
diabetes 1 10.0 2 4.0 2.7 0.443 
Note: • greater than 0.9, not rounded to show presence or absence of overlap with null; patients (pts) 
~0.2 - 323.6~ 
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8.2. Multivariate Models 
Three multivariate conditional regression models were built to describe relationships 
between SHLA and variables collected at baseline and over time prior to case 
diagnosis. A further 2 multivariate models consider cases only and were performed 
using logistic regression analysis. The first of these looks at associations with the 
severity of SHLA and the second looks at variables associated with mortality among 
the cases. 
8.2.1. Risk factors during the beginning months on ARV 
therapy 
This first model contains data from the study participants which describes the time 
period before manifestation of signs or symptoms related to SHLA, identifying 
characteristics of patients who may at the outset be at a greatest risk of developing 
SHLA. According to this model (Table 14), cases were 23.4 times (95% CI 4.0-
136.6) more likely to be female than controls. Patients with SHLA were 4.5 times 
more likely (95% CI 1.4 14.1) to have a baseline weight of60 -74.9 kg, and had a 
19.4 increased likelihood (95% CI 4.6 - 82.5) of weighing 2: 75 kg in comparison to 
people weighing less than 60 kg. During the first three months on ARV therapy, 
cases were 3.5 times more likely (95% CI 1.3 - 9.5) to have gained at least 6 kg in 
comparison to controls. This conditional regression model was adjusted for nadir 
CD4 count and age. 
Table 14: Multivariate analysis of risk factors for SHLA at baseline and first 3 months on ART 
Dependent variables OR p-value 950/0 CI 
CD4 count nadir, per 50 cellslmm3 0.8 0.305 (0.6 - 1.2) 
Age, per 10 years 1.6 0.117 (0.9 - 2.9) 
Female 23.4 <0.001 (4.0 - 136.6) 
Baseline weight <60 kg ref. cat. 
Baseline weight 60 to 75 kgs 4.5 0.009 (1.4 - 14.1) 
Baseline weight ?:.75 kg 19.4 <0.001 (4.6 - 82.5) 
> 6 kl weilht lain in first 3 months on ART 3.5 0.013 !1.3 - 9.5) 
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8.2.2. Risk factors during follow-up consultations 
This second model (Table 15) considers all variables collected at baseline and during 
follow-up consultations at the primary health care clinics, and intended to identify 
additional potential risk factors related to interventions, as well as the signs and 
symptoms most closely associated with case status. Cases with SHLA were 12.4 
times more likely (95% CI 1.8 - 85.4) than controls to have had a gain in AL T of at 
least 10 UIL (from baseline to peak values reached prior to diagnosis). Cases with 
SHLA were at 23.9 greater odds (95% CI 2.8 - 204.9) oflosing at least 3 kg during 
the last 3 months prior to diagnosis in comparison to the controls. AL T gain and 
weight loss was adjusted for age and the patient's CD4 count at 6 months. 
An AL T threshold of~40 UIL was also substituted for ALT gain in the below model. 
This substitution did not change the direction of the odds ratios or significance of the 
CIs for the other variables; however it did not prove to be a better fit. Patients with 
SHLA were 4.5 times more likely to have had an ALT level of~ 40 UIL during the 
study period (95% CI 1.26 - 16.31). 
Table IS: Multivariate analysis of risk factors for SHLA during follow-up (Modell) 
Dependent variables 
CD4 count at six months, per 50 cellslmm3 
Age, per 10 years 
AL T gain (from baseline to peak) <10 UIL 
AL T gain (from baseline to peak) ~ 1 0 UIL 








(0.5 - 1.2) 
(0.3 - 2.1) 
(1.8 - 85.4) 
(2.8 - 204.9) 
This following model (Table 16) also characterizes associations with SHLA amongst 
data collected at baseline and during follow-up consultations; however it excludes the 
variable measuring the gain in AL T, as small numbers were complicating the model. 
According to this model fit, cases were at 10.7 greater odds (95% CI 2.7 42.0) of 
having experienced at least one of the three major symptoms related to SHLA 
(abdominal pain, vomiting and/or nausea) during the 80 days prior to case diagnosis. 
Patients diagnosed with SHLA were 11.5 times more likely (95% CI 3.0 - 44.6) to 
experience weight loss of at least 3 kg in the 3 months prior to case presentation in 
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comparison to the controls. In this regression, rapid weight gain became less 
significant as the major symptoms, including weight loss, dominate the model. 
Weight gain and loss, and major symptoms were all adjusted for the baseline CD4 
count. Age was dropped from the model, due to complexity, and was not associated 
with the outcome. 
Table 16: Multivariate analysis of risk factors for SHLA during follow-up (Model 2) 
Dependent variable Odds Ratio P> value 95% CI 
CD4 count nadir, per 50 cells/mm3 
Major SHLA symptoms (in 80 days prior to study end) 
2: 6 kg weight gain (first 3 months on ART) 









(0.5 - 1.2) 
(2.7 - 42.0) 
(0.8 - 8.3) 
(3.0 - 44.6) 
8.2.3. Risk factors associated with lactic acidosis amongst the 
cases 
In order to consider the severity of the diagnosis, those patient with both a standard 
venous bicarbonate and a pH laboratory result at diagnosis were split into two groups, 
cases that met the definition of having lactic acidosis (standard bicarbonate <20 and 
ph<7.35) and cases that had the less severe condition, namely SH. As the cases were 
no longer matched to controls, a logistic regression was performed (Table 17). 
Patients with lactic acidosis were 17.8 times more likely to have a creatinine reading 
of~ 77 mmollL compared to patients with creatinine levels lower than 77 mmollL in 
their blood at the time of diagnosis. The odds ratio of 5.2 suggests that patients who 
gained greater than 6 kg of weight during their first 3 months on therapy were at 
greater odds of experiencing lactic acidosis, however as the confidence interval 
crosses the null the ratio could be due to chance alone (95% CI 0.8 - 34.0). 
Table 17: Multivariate logistic regression of risk factors for lactic acidosis amongst cases 
Dependent variables OR p-value 95%CI 
creatinine<77,l..ImollL reference category 
creatinie>77, J,1mollL 17.8 0.002 (2.8 - 113.2) 
2: 6 kg weight gain in first 3 months on ART 5.2 0.084 (0.8 - 34.0) 
• base excess not fit into model as it measures acidosis 
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8.2.4. Risk factors associated with mortality amongst the cases 
Attempts were made to find associations between variables collected in the study and 
mortality amongst cases. The venous standard bicarbonate level at case diagnosis was 
the only variable that stayed in the model when considering associations between 
cases and mortality. Patients who died tended to have lower venous standard 
bicarbonate levels in comparison to those who recovered from SHLA (OR O.S per 
mmollL increase in venous bicarbonate; 95% CI 0.7 - 0.9; p=O.OOS). 
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9. Discussion 
9.1. Key Findings: 
This study capitalises on the cohort monitoring system in the Western Cape and one 
of the largest case series of SHLA in order to provide a comprehensive analysis of the 
risk factors, signs and symptoms of patients suffering from SHLA. It is also one of 
only three SHLA studies undertaken in the context of wide-scale up in South Africa 
using WHO recommended regimens, and the only in-depth SHLA study using 
controls to quantify associations. The study further presents a first effort to include 
longitudinal follow-up variables, above and beyond laboratory findings, in a case-
control study on SHLA in the South African setting. 
9.1.1. Duration on ARV Therapy 
Ninety five percent of all SHLA cases occurred between 6.5 and 17.1 months duration 
in the South African setting. All cases were on d4T prior to case presentation or had 
recently been switched off d4T due to severe symptoms. These two findings suggest 
that HIV health care workers should be especially vigilant to signs and symptoms of 
SHLA in patients on d4T from 6 months to 18 months duration on ART. 
Other studies have also reported a similar window of risk for SHLA ( <20 moths) in 
patients on ARV therapy?7,28,3o,33,36,37 A study by Imhof and the Swiss HIV Cohort 
Study plotted the probability of an elevated lactate level (>2.4 mmollL) during the 
first four years of ARV therapy. The slope was the greatest between baseline and two 
years on therapy.33 A further two studies, one by Boffito et al. and one by John et ai, 
found that patients with NRTI exposure are at higher risks of elevated serum lactate 
levels within their first year oftherapy.6.38 It appears that the majority of patients 
adapt to their elevated lactate levels, which tend to reach a plateau and then stabalise 
over time via compensatory mechanisms of the body. However, those few patients 
that continue to develop SHLA are in severely deteriorated metabolic states in which 
homeostasis is not re-gained until ARV therapy is discontinued.6,38 
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9.1.2. Adult case referral rate 
Overall, there were 67 patients referred from the G.F. Jooste primary health care 
drainage sites, giving a total of 5,989 patient years and a referral rate of 13.5 SHLA 
cases per 1000 patients. Thirty-five of the 67 cases had confirmed LA, with a 
corresponding referral rate of 7.1 cases per 1000 patient years. These referral rates 
may underestimate the incidence of SHLA due to the possibility of patients passing 
away at home without diagnosis. More interestingly, it is important to note that ARV 
services that have been open longer have lower referral rates. This makes sense when 
one considers the short window of risk from 6 to 18 months on ARV s for 95% of the 
cases. As a clinic's population of patients receiving ARVs for longer than 20 months 
increases, their referral rate will decrease proportionally. 
Discrepancies in reported incidence rates ofSHLA are not only due to the variety of 
case definitions and first line regimen choice, but also due to the maturity of the ARV 
cohorts being studied. Literature shows a case rate for SHLA between 1.1 and 30.8 
cases per 1,000 patient years.2,5,7,12,15,27,28,37 One study in France by Bonnet et al. 
reported 1.1 LA cases per 1000 years, while another study in South Africa by Geddes 
and colleagues reported 14 cases of lactic acidosis per 1000 patient years. The cohort 
in Bonnet's study covered patients on ARV therapy over four years, while Geddes's 
study looked at patients on ARV therapy over a one and a half year period. The case 
referral rate in Bonnet's study included many additive months of patient time when 
they were not at risk of SHLA in comparison to the Geddes study, which may 
partially explain the lower incidence rate. 15,28 
In attempts to propose a standardized way to compare referral or incidence rates of 
adverse events with discreet windows of risk amongst different cohorts across the 
world, a new calculation for incidence rates was considered. The new calculation 
considers only the months a patient contributes when they are at risk for the adverse 
event, for SHLA this translates into only counting up the months between 6-18 
months on ARV therapy. Using these parameters, the overall referral rate for SHLA 
was 32.1 cases per 1000 patient years and 16.8 cases of lactic acidosis per 1000 
patient years in the G.F. Jooste referral cohort. This new calculation was used to look 
at the referral rates of each different referral clinic as a way to validate the tool. After 
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stratifying by referral clinic, it was revealed that there was a wide range of referral 
rates, with the older ARV services referring fewer cases then the newer sites. There 
may have been more knowledge and shared experience resulting in higher vigilance 
amongst the older clinics, as they have been seeing such cases for longer periods of 
time and were more likely to be doing point of care testing. For these reasons, there 
may have been more drug substitutions from d4T to AZT at the primary health care 
level in patients whose lactates were not sufficiently raised to require referral. As the 
setting is reasonably uniform, these differences suggest that local clinical practices 
can dramatically impact on the referral rates to hospitals for SHLA, and warrants 
further exploration. 
9.1.3. Factors associated with case status 
ARV drugs 
All cases had been exposed to d4T during their ARV therapy, and not one d4T naive 
participant during the 27 months of this study suffered from SHLA. Although the 
case-control study was matched by duration on ARV therapy, many patients (n=26) 
experienced NRTI drug substitutions during the study period. In an effort to look at 
AR V drugs as risk factors, any patient receiving 100 days or more of a particular 
ARV drug was recorded as positive for that drug (the first case presented 108 days 
after commencing ARV therapy). 
Only d4T at a dosage of 40 mg twice a day for;::: 100 days showed as a strong risk 
factor during univariate analysis for SHLA in comparison to other ARV drugs. All 
patients above 60 kg were automatically put on 40 mg of d4T twice a day according 
to protocol. Therefore, in the South African context, a heavy baseline weight above 
60 kg and d4T 80mg per day are directly correlated. Untangling the two risk factors, 
in this type of non-experimental study, cannot be done and any associations between 
either of the risk factors would need to be interpreted with consideration to the other 
risk factor. 
During the 14th Conference on Retroviruses and Opportunistic Infections (CROI) the 
WHO decided to change their protocol to recommend that no patients receive d4T at a 
dose greater than 30 mg twice a day. This is expected to lower the incidence of 
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SHLA, however health care workers and patients alike will still need to remain 
vigilant as 4 cases in this study were on 30 mg of d4T twice a day for the entire 
duration of the study. 
All cases were on d4T prior to diagnosis and the duration on therapy was matched in 
this case-control. The lack of variance in d4T with regards to case status did not 
allow for measuring the odds of d4T being associated with SHLA. Therefore, it was 
not possible to adjust for d4T in the multivariate regressions. 
It is possible however, that given the known strong associations between SHLA and 
d4T exposure that clinicians may have been more likely to look for and ascertain 
SHLA in patients on d4T compared to other patients. 
Gender 
According to the multivariate regression, female patients on d4T are at a much greater 
risk of developing SHLA when compared to males. This finding has also been 
reported in many international studies.2,5,28,29,39 The different multivariate models 
presented in this case-control show that patients with SHLA are 23.4 times more 
likely to be female; however the magnitude of the odds ratio may be misleading. 
There were only four male cases and 67 female cases. During regression in STAT A, 
the variables are adjusted for each other and stratified into cells. If there is a lack of 
variance among a variable (for example, few males and many females), some cells 
will have very low numbers of observations in them. This can lead to a distortion of 
the odds ratios. As females are over-represented in this study, the odds ratio may be 
biased away from the null, but this does not negate the finding that being female 
remains a strong risk factor for SHLA. 
Many studies have reported that females are overrepresented amongst the cases in 
comparison to the proportion of females on ARV therapy in the source populations, 
2,5.28,29 however the only other published study the author found that quantified the 
association was by Boulle et al. In this South African study, female gender was 
reported as 10.7 times more likely to have d4 T substituted with another drug due to 
symptomatic hyperlactataemia or LA (hazard ratio, 10.7; 95% CI 1.5 - 79.0).16 
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Baseline weight and initial rapid weight gain 
There have been very few studies that have looked at baseline weight as a risk factor 
for SHLA. Falco et al. reported in their review of cases in the literature, that cases 
tended to have higher body mass indexes, although this risk factor was not analysed in 
multivariate analysis.37 In the multivariate regression analysis of factors at baseline, 
the current study showed that cases with SHLA were more likely to have a baseline 
weight of~ 60 kilograms (60 - 75 kg OR 4.54; 95% CI 1.45 - 14.11; ~75kg OR 
23.39; 95% CI 4.00 - 136.63). The rapid increase in risk with increasing weight 
cannot be explained by dose escalation at 60 kg, and suggests a biological 
phenomenon peculiar to women with high BMI's. 
Patients that experienced rapid weight gain of 6 kg or more in the first 3 months of 
therapy were 3 times more likely to suffer from SHLA when compared to patients 
who did not gain at least 6 kilograms during the same period. 
The literature review described a putative biological mechanism espoused by some 
clinicians that could link both baseline weight and rapid initial weight gain with the 
risk ofNAFLD, which in tum could predispose to SHLA. As a fatty liver is less able 
to metabolize lactate, it may become a net producer, contributing to the build-up of 
lactate in the blood causing metabolic complications including SHLA.4 
David Sass reported many conditions associated with fatty liver disease including 
obesity, diabetes mellitus, total parental nutrition, rapid weight loss and nucleoside 
analogs. Interestingly, Sass also reported a connection between patients with 
hypothalamic/pituitary dysfunction, whom were at risk of excessive weight gain, as 
being found to develop progressive NAFLD. 19 
The diagnosis of non-alchoholic fatty liver (NAFLD) and non-alcoholic 
steatohepatitis (NASH) cannot be confirmed unless a biopsy of the liver is taken. 
Liver biopsies are hotly debated due to the risk, cost and lack of effective medical 
therapy for these conditions. For this reason, the prevalence of fatty liver has not been 
reported in the South African setting as far as the author is aware of. However, 
prevalence rates reported worldwide have been shown to be between 10-24% in 
various settings. The prevalence figure increased to 57.5 -74% amongst obese 
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individuals. 19.23 Another study in Italy on NAFLD, using ultrasound techniques, 
found that all 187 young patients with a BMI of2':30 had some degree of liver 
steatosis. 17 In this case-control study, 50% of the cases with heights measurements 
were considered obese (BMI>30), and another 30% had BMIs > 25. If the prevalence 
offatty liver is comparable to that in the states, a large proportion of the cases had 
NAFLD before ever starting ARV s. Rapid weight gain may further aggravate an 
asymptomatic patient with progressive or potential NAFLD, causing a build-up of 
lactate in the body. 
Laboratory Results 
Not one of the clinical parameters at baseline indicated any association with an 
outcome of SHLA during univariate analysis. Both the cases and controls in this 
study had very low nadir CD4 counts not allowing for an association to be seen. 
However, a study by Bonnet et al reported an association between low nadir CD4 
counts «250 cells/mm3) and SHLA.18 Assessing measurements during ARV follow-
up appointments revealed that an AL T gain of ten or more UIL between baseline and 
the peak was strongly and independently associated with case status (OR 12.4; 95% 
CI 1.8 85.4). Over 50% of the cases gained at least 10 UIL of ALT during the study 
time period. An AL T result of greater than 40 UIL during the study period was also 
found to be significant, but not as strongly associated (OR 4.54; 95% CI 1.3 - 16.3). 
Literature has shown that raised aminotransferase levels were predictive of NAFLD in 
42-90% of cases, after excluding other causes of liver disease. 11 
The gain in AL T was also looked at in the last 80 days prior to diagnosis, but only 26 
cases and 29 controls had measurements at both baseline and during the 80 days prior 
to case presentation. There was not enough power to show any association in 
univariate analysis with SHLA, however the magnitude of the odds ratios were big 
and increased with the increased gain in the AL T measurement. This suggests the 
possibility that had there been a larger number of AL T measurements taken during 
this period, an association may have been seen. 
Wei&ht loss in the last 3 months prior to case presentation 
Patients developing SHLA clinically deteriorate over time. One of the early signs of 
SHLA includes weight loss. Fifty-nine of the 71 (90.8%) cases experienced weight 
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loss prior to diagnosis ofSHLA, and 34% of the cases suffered weight loss of3 kg or 
more during this time period. During multivariate analysis patients with SHLA were 
more likely to experience weight loss of?: 3 kilograms prior to the case presentation 
date. This finding could have important clinical significance, as any patient on d4T 
who begins to lose weight should be assessed for other signs or symptoms of SHLA, 
especially if the weight loss happens during the 6-18 month time period on ARV 
therapy. 
WHO stage defining illnesses 
The different WHO clinical stages were not associated with case status in multivariate 
analysis due to the power of this study. However the odds ratios increased per WHO 
stage, suggesting a dose effect, with patients more severely immuno-compromised 
potentially being at greater risk for SHLA. 
The number of patients experiencing a particular WHO stage defining illness prior to 
commencing ARV therapy were small (:SID cases and/or 10 controls), except for 
tuberculosis and oral candidiasis. Even though the analysis lacked power, it is 
important to point out that cryptococcal meningitis did reveal an odds ratio of 8 (95% 
CI .9 -71.6). This considerable odds ratio warrants further research into a possible 
association. Both prior tuberculosis and oral candidiasis were not found to be 
associated with SHLA. 
Symptoms during the 80 days prior to case presentation 
Various exploratory analyses were performed to try and capture preceding symptoms 
and present them in a quantifiable way. Exploratory analysis was performed for 
symptoms as ever having had the symptom, as a median time period for when the 
symptom first started to case presentation and the combination of symptoms cases and 
controls experienced. 
The final model captured symptoms regressed as binary variables, with ever having 
the symptom in the stated time period as being indicative of exposure. By assessing 
symptoms amongst the cases and controls during the 80 days prior to case 
presentation, one would expect many of symptoms to show association with SHLA, 
as one is comparing an increasingly sick population (cases) to a relatively healthy 
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population (controls). Although this confined time period of symptom analysis will 
push the odds ratio away from the null in comparison to measuring the same 
symptoms during the entire study period, it an important analysis to describe exactly 
how the cases presented in contrast to controls in the weeks prior to diagnosis. 
Symptoms were categorized as ever having been recorded in the patients' folder in the 
80 days prior to the case diagnosis. The symptoms, during univariate analysis, found 
to be associated with SHLA are not unique to this syndrome, but also tend to describe 
many HIV -related illnesses. The strongest associations, with odds ratios> 10, include 
abdominal pain, poor appetite and vomiting which were also closely linked in timing 
of onset to case presentation. Associations between SHLA and facial and limb 
swelling, puritic or red eyes and heartburn (lack of controls makes OR impossible to 
estimate) have not previously been described, but were also temporally more distal to 
the event. Symptoms of sexually transmitted diseases, headaches and rashes were not 
found to be associated with SHLA. 
The concurrent clinical manifestations of lipodystrophy and peripheral neuropathy, 
which have overlapping pathophysiological mechanisms, were also both found to be 
correlated with SHLA during univariate analysis, but did not stay in the models 
during multivariate regressions. 
Perhaps, more importantly, from a health provider's perspective, it is the combination 
of the above symptoms that should alert one to suspect the possibility of SHLA. The 
cases had a median of four different symptoms (IQR; 1-6) prior to case diagnosis, 
while controls had a median of 0 symptoms (IQR; 0-1). 
Additional medications other then ARVs 
Associations in univariate analysis between SHLA and hyoscine butylbromide, 
ibuprofen, loperamide and metoclopramide were found. Although there were some 
associations between occasional medicines and case status, the compounds were most 
likely prescribed due to symptoms of the developing condition rather than being 
causes of the condition, and these associations should be treated with extreme caution. 
In addition, there were no biological mechanisms that could be identified linking these 
compounds to the outcome. 
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9.1.4. Variables associated with LA amongst the cases 
Cases diagnosed with LA were more likely to have raised creatinine levels in their 
blood compared to cases presenting with the milder form of this condition, SH. LA 
cases also appeared to gain weight more rapidly then patients diagnosed with SH, 
although this finding was not significant, containing wide confidence intervals that 
crossed over the null. 
Creatinine levels are taken to evaluate kidney function; when the kidneys are 
functioning abnormally creatinine levels in the blood will increase. Mitochondria 
playa crucial role in cellular metabolism and energy metabolism. When the numbers 
of mitochondria decrease or they function irregularly it is not surprising to see effects 
that involve many organ systems, including the kidneys? As kidneys are lactate 
consumers, any damage may further increase the levels of lactate in the body. 
9.1.5. Variables associated with mortality amongst the cases 
The only variables, during multivariate logistic regression, found associated with 
death amongst the cases were measures of acidosis, of which standard venous 
bicarbonate was the measure most closely associated with mortality. Cases that 
passed away were more likely to have decreased venous standard bicarbonate levels 
in comparison to the milder form of the syndrome (SH). Although associations were 
found with the level of lactate elevation during crude analysis, this fell away when 
adjusted for acidosis by venous standard bicarbonate. 
As the standard bicarbonate levels reflect the degree of metabolic acidosis, clinical 
manifestation is more severe and rapidly worsening in patients with low standard 
bicarbonates.2 The only study found that spoke about bicarbonate levels, was the 
study by Geddes and colleagues. Although their study did not assess associations 
with mortality, 3 of the 4 patients that died had the three lowest bicarbonate values 
(range, 6.3 - 8.3 mmollL).28 
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9.2. Strengths and Weaknesses 
This is the largest case-control study on SHLA that the author is aware of, with 71 
cases and 142 controls. It is also the first case-control that has looked at longitudinal 
variables including clinical parameters and symptoms. It is one of three studies 
conducted in Southern Africa and in the context of rapid scale up of ARV therapy 
according to WHO recommended regimens. It is the only case-control study of 
SHLA in this setting. As part of the Western Cape Cohort, all clinics are public 
health sector facilities and therefore use the same regimens, laboratory tests and 
provincial protocols for managing an ARV service. 
Study design 
SHLA is a rare outcome of patients on ARV therapy. The case-control study is the 
most efficient sampling technique to reach statistical power for determining risk 
factors and possible diagnostic tools of rare outcomes, making it the most appropriate 
design for this study. 
Matching 
Matching limited the ability to look at drug durations as a risk factor. However, 
universal use of d4 T and matching by duration has taken out two of the strongest 
associations with SHLA, allowing us to look at other risk factors in more detail. 
Incidence density sampling 
In this study, incidence density sampling was used while selecting the controls for the 
study. With incidence density sampling the controls represent the exposure odds 
which equates to the ratio of person-years of observation of exposed and unexposed. 
Therefore, the odds ratio from this case control study equals the rate ratio in the 
underlying cohort study. Ten controls later came down with SHLA after their 
matched-case diagnosis date, and many more had stavudine substituted to another 
drug due to peripheral neuropathy or lipodystrophy. 
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Categorizing exposure variables for analysis 
As briefly mentioned in the methods section 6.6, information related to each 
individual symptom and drug were grouped into binary variables, with exposure being 
positive if they ever experienced the variable within the stated time period that the 
variable was being considered. Duration of a symptom is often very difficult to 
ascertain. However, poor record keeping limited the analysis of duration of drug 
exposure (other than ARVs). Analysis would have been more robust had duration of 
exposure to a medication been recorded, but due to many ofthe patient's folders 
lacking a stop date, this type of analysis could not be made, weakening the overall 
results of the study pertaining to occasional drugs. 
As symptoms were sometimes poorly recorded, grouping variables into binary 
exposures meant that patients with an unrecorded symptom had that information 
aggregated in the data set as not having had the exposure. The same problems existed 
with analysis of the occasional medications, with poorly recorded data making the 
duration of the medications unattainable. 
9.3. Potential Bias 
Recall bias 
This is a nested case-control study, with the cohort being all patients on ARV therapy 
within the public health sector of the Western Cape Province. Collection of patient 
information (later used as variables in this study) at facility level was part of routine 
assessment during follow-up appointments in the health facilities; therefore potential 
exposures were recorded prior to case status. Recall bias was thus avoided by the 
design of this study. 
Selection bias 
Case-control study results are heavily influenced by selection bias. With this 
knowledge careful attention was paid to ensure that both cases and controls would 
represent the probability of exposure in the source population. 
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All cases reported from the G.F. Jooste Secondary Referral Clinic during the time of 
the study period, were included in this study with the exception of two patients. The 
two patients not included were referred from a site that does not partake in the public 
health sector roll-out, making their folders difficult to access. As the two patients 
were not excluded due to any knowledge of treatment or exposure information, 
selection bias of the cases was not influenced from their exclusion. 
Controls were matched to cases according to ARV commencement month, which due 
to incidence density sampling meant ARV duration as well, and facility. The controls 
were randomly selected from the group of eligible patients that also met the above 
stated matching criteria. The matching technique was not chosen intentionally to 
ensure that possible confounders were equally stratified in analyses, but due to 
practical reasons (as explained in the methods section 6.1). However, matching by 
facility had the additional benefit of ensuring that confounding due to resources or 
different management protocols of patients at the primary ARV sites would not have a 
big impact on the results (for example, health staff to patient ratios, doctor heavy 
compared to nurse heavy sites, site differences pertaining to amount of time between 
patient clinical visits, etc.). Matching by ARV start date allowed potential 
confounding due to provincial policy change over time to be stratified equally across 
cases and controls (for example, the policy of taking baseline viral loads, and the use 
of nevirapine versus efavirenz changed during the study period, as did the availability 
oflactate meters at each ARV facility). Matching by ARV duration unfortunately 
meant that this variable could not be analysed overall in the study. As shown in this 
study, cases presented during a window of 3 to 30 months on ARV therapy. As new 
patients were being initiated on ARVs at relatively fast rates during the early stages of 
the public roll-out, direct random selection of controls would have resulted in more 
controls with shorter ARV duration periods compared to the cases. 
In addition, controls were selected if they met the eligibility criteria, regardless of 
exposure information and whether they had manifestations of the studied condition 
after the matched cases diagnosis date. As a result, controls were free of the disease 
at the matched case diagnosis date, but represented those at risk in the population of 
becoming cases. 
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Referral bias 
As G.F. Jooste Hospital is the referral route for serious adverse events of patients on 
ARV therapy in their area, and also well-known to have expertise in the area of 
SHLA, it is unlikely that cases from the source population would have been referred 
elsewhere. It is therefore unlikely to have a group of cases with different rates of 
exposure not being measured (unless cases passed away before being referred). 
Investigator bias 
Every attempt was made to ensure that investigator bias did not enter into the study. 
Per study design, all symptoms, laboratory results, clinical diagnoses, medications and 
weights recorded in patient folders during the study period were collected in the 
database for potential analysis. This excluded any bias in regards to decision making 
of whether or not to collect a recorded piece of information regarding the above 
variables during the collection period. 
Ascertainment bias and misclassification 
As patients at the primary health site started showing signs of clinical deterioration, 
many symptoms recorded may have been elicited by the health care providers 
initiative to ask sick patients whether they had been experiencing such symptoms, 
where as relatively healthy patients probably were not asked as many direct questions 
relating to symptoms (in relatively healthy patients recorded symptoms were more 
likely due to complaints initiated by the patient). This probably resulted in symptoms 
that were not severe being more frequently recorded in patients experiencing clinical 
deterioration, resulting in differential misclassification, biasing the odds ratio away 
from the null. 
More investigative techniques, such as laboratory tests and more in-depth physical 
examination could have occurred in sicker patients as well, together with more 
frequent consultations, resulting in ascertainment bias. 
The level of clinical record keeping varied at the different primary care facilities and 
most likely also varied between the different health-workers within each facility 
performing the clinical follow-up visit. Poor record keeping resulted in non-
differential misclassification biasing results away from the null. 
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Differential misclassification during analysis 
In order to limit differential misclassification of exposure status during analysis, 
symptoms and laboratory results recorded at the case diagnosis site (O.F. Jooste 
Secondary Referral Hospital) were not included in the analysis comparing case and 
control variables in association to SHLA. Clinicians at the O.F. Jooste Secondary 
Referral Clinic have more training in ARV complications and making deductions 
during a diagnosis of complex diseases. As they are the referral centre for complex 
ARV patients in the area, they also have more practice than a clinician or health care 
worker at a primary site. By trying to ascertain what condition a patient is suffering 
from, more questions regarding symptoms and exposure would be recorded. It was 
assumed that cases sent to this referral site would have extensive infonnation recorded 
during their diagnosis visit/so As controls did not get this same 'more intensive' 
follow-up session at their primary site, notes from the case folders at O.F. Jooste were 
not included in the analysis of associations with SHLA. 
Infonnation collected during the referral visit/s was/were used in the analysis of 
associations with LA in comparison to SHLA though, and in the analysis of mortality 
in the cases. The inclusion of the referral infonnation during these analyses did not 
create additional bias, as all controls were dropped from this analysis. 
10. Future Studies 
According to the old South African protocol, all patients over 60 kg were 
automatically started on or changed to a 40 mg dose of d4T twice a day. As the WHO 
has recommended all patients be given a twice daily 30 mg dose of d4T, regardless of 
weight, risk factors relating to weight would need to be re-established in patients 
reaching weights of greater than 60 kg while on a d4T containing ARV regimen. 
There is very little infonnation about how a BMI relates to SHLA and lactic acidosis. 
As the BMI is a much better measure of obesity than absolute weight, this variable 
should be looked into more extensively. 
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When larger case series are available, findings related to weight should also be 
con finned in men. If increased baseline weights or BMIs are not found to be 
associated with the male gender, interactions between female gender and weight 
should be analysed. 
Genetic studies into patients at a higher disposition of SHLA should also be 
considered. The patient population in this study was relatively unifonn; therefore, 
risk factors relating to different populations could not be assessed. The paucity of 
research on this subject warrants further studies. 
A further look into different clinical practices that may reduce the incidence of SHLA 
should also be considered. 
11. Conclusion 
As d4T remains the preferred choice making up part of the NRTI backbone of ARV 
therapy in developing countries, the morbidity and mortality associated with d4T use 
should be minimised as much as possible. As cases of SHLA continue to rise in 
Southern Africa in correlation to increased accessibility of ARV therapy, preventative 
measures should be put in place to decrease such illnesses and death in instances 
where the risk factors are clearly identified. 
The majority of cases presented in a narrow window of time between 6 and 18 months 
duration on ARV therapy. Treatment with stavudine, female gender, initial weight (2: 
60 kg, but especially 2: 75 kg), and rapid early weight gain (2: 6 kg) are confinned as 
the dominant factors identifying patients who may subsequently develop SHLA. 
Weight loss (2:3 kg), the major known symptoms ofSHLA (abdominal pain, nausea, 
and vomiting), together with ALT gains (2:10 UIL) during follow-up are the clinical 
parameters that are most able to identify patients about to develop SHLA. 
Biochemical parameters reflecting acidosis are the only factors associated with acute 
mortality amongst the cases, whilst a raised creatinine at case presentation is 
additionally associated with severity of disease. 
According to these results, it is recommended that overweight women not be started 
on d4T containing regimens. Any patient on d4T that gains greater than 6 kilograms 
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during their first three months of ARV therapy or any patient losing weight should be 
monitored carefully for symptoms of SHLA. The use of AL T in identifying patients 
at risk requires further exploration. 
Strategies to prevent morbidity and mortality on a programme level include 
considering other first line ARV drug choices such as tenofovir, and clinical 
interventions that promote the identification of patients at risk both when initiating 
therapy (when alternatives could be used in these patients), and during follow-up 
(where early substitution of stavudine could prevent subsequent disease). Even in 
countries that adopt the WHO recommended dose decrease in d4T, vigilance needs to 
remain high as four cases in this study were on the decreased d4T dosage throughout 
their entire duration on AR V therapy. 
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Table 1: Model building for risk factors at the start of ART 
Log prob 
Step Model Variables obs likelihood chi2 >ch12 Ale SIC 
• constant • case 213 -79.02 
i b cd4_nadlr 196 -68.20 0.96 0.3265 138.39 141.05 c WHO stage 209 -77.52 0.00 0.9501 157.03 160.38 
c i ............ ; ...... ·i!· ~;diri (~g~}'.'.'.'.'.'.'.'.'.'.'.' .......... ;j~ ... ~:·i~··· +~; .... ~:m: ... ~~~···m:~ 
interactions f (cd4 nadlr)(age) (cd4Jladlr"age) 177 -65.76 1.43 0.6975 137.53 147.12 
9 (cd4_nadlr) (age) (wt_basa) 178 -53.66 24.46 <0.0001 113.33 122.87 
h (cd4_nadir) (age) (female) 190 -54.91 30.98 <0.0001 115.83 125.57 
I (cd4_nadlr) (age) (wt_3mg6) 169 -59.37 6.21 0.1019 124.75 134.14 
•.•...•.•.• .1 .•.•.• .lC!-l~_f!I!«!irllli'll~l ~~P!?!Y.P,tg>- .•...•.........•.•.•.• :!'9I1 .• ::!l~~~ .•.•. ~:!!5 •.•. ~:!~ ... ~~1~~. _ .1~t·!'P. 
k (cd4_nadir) (age) (wt...basa) (female) 178 -39.89 52.01 <0.0001 87.78 100.51 
I (cd4_nadir) (age) (wt_basa) (wt_3mg6) 169 -48.84 27.27 <0.0001 105.68 118.20 
•.•.•.•.•.•. !'! •.•.•. 1~_n!~Jr)J!ljl.eJ.lwt ... '!!i!s..t!l(~!l) _. _ .•.•.•.•.•. 1!! .•. ~~ .. I!.0 •.•. ~~~1.~ .•. ~~~~! ... 1..1.~.!!!l .•. H~:~~ 
n (cd4_nadlr) (age) (wt_basa) (female) (wt_3mg6) 169 -33.07 59.18 <0.0001 76.14 91.85 
•.•.•.•.•.•. ~ .•.•.•. 1~~~~!I!I~irJ.(!ljleJ.(.M ... b.~I!.t!l(f~a!!,,)J.~L .•.•. !!L. :~:~2 •.•. ~~~ .•. ~~~! ... ~~~~ ... !~'.~ 
P (cd4_nadir) (age) (wt_base) (female) (wt_3mg6) 
(bpCrypto) 169 -36.37 52.21 <0.0001 84.74 103.52 
Interactions q (cd4_nadir) (age) (wt_base) (female) (wt_3mg6) 
(wt_base"female ) 169 -36.67 51.62 <0.0001 85.33 104.11 
& r (cd4Jladir) (age) (wt_base) (female) (wt_3mg6) i (wt_basa"wt_3mg6) 169 -35.86 53.23 <0.0001 83.73 102.51 
... 
.. 
• (cd4_nadir) (age) (wt_base) (female) (wt_3mg6) i2 (female"wt_3mg6) 169 -36.80 51.40 <0.0001 85.56 104.34 
t (cd4_nadlr) (age) (wI_basa) (female) (wI_3mg6) 
( cd4_nadlr'wt_base) 169 -36.78 51.39 <0,0001 85.56 104.34 
u (cd4_nadir) (age) (wi_base) (female) (wI_3mg6) 
(cd4_nadir"female) 169 -32.59 59.77 <0.0001 79.19 101.10 
v (cd4_nadir) (age) (wt_base) (female) (wt_3mg6) 
(cd4_nadlr"wt.. 3mg6) 169 -34.59 55.78 <0.0001 83.17 105.08 
w (cd4_nadir) (age) (wt_base) (female) (wt_3mg3) 
(age"wt_base) 169 -35.00 54.95 <0.0001 84.00 105.91 
x (cd4_nadlr) (age) (wt_base) (female) (wt_3mg6) 
(age"female) 169 -31.85 61.26 <0.0001 84.00 99.48 
Y (cd4_nadir) (age) (wt_base) (female) (wt_3mg6) 
(age"wt 3mg6) 169 -36.84 51.67 <0.0001 85.29 104.07 
"''''nona or the iII1eractton vanables showed s'1lnilicance dunng ragresslOll 
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Table 2: Model building with ALT 
Log prob 
Step Model Variables obs likelihood chl2 >chi2 AIC BIC 
constant • case 213 -79.02 
z OO4_nadlr 196 -68.20 0.96 0.3265 138.39 141.05 
; c WHO stage 209 -77.52 0.00 0.9501 157.03 160.38 
..., 
b 004_06 182 -64.35 4.36 0.0369 130.71 133.91 c 
i .•.•.•.•.•.• ~ •.•.•.• '\Ill! •.•.•.•.•.•.•.•.•.•.•.•.•.•.•.•.•.•.•.•.•.•. l-.o..~ .. :~:R .... ~ ~2.~ .•. • ~J.?..1.! .• . !~:~ .. 1?1:!!. e (004 06l (aael 177 -61.79 5.91 0.0520 127.57 133.92 
InteractionS h (004_06) (age) (OO4_06*age) 177 61.43 6.62 0.0851 128.86 138.39 
I (004_06) (age) (wt_base) 162 46.96 24.58 <0.0001 99.92 109.18 
J (004_06) (age) (female) 177 -49.90 29.69 <0.0001 105.79 115.32 
k (004_06) (age) (wt_3mg3) 156 -52.72 8.66 0.0342 111.44 120.59 
I (004_06) (age) (wt3m.,prasloss3) 146 -37.29 30.50 <0.0001 80.57 89.52 
m (004_06) (age) (allg) 106 -32.43 11.68 0.0086 70.86 78.85 
n (004_06) (age) (biJamaj) 177 -31.92 65.64 <0.0001 69.84 79.36 
P (cd4_06) (age) (bvomil) 177 -39.84 49.80 <0.0001 85.68 95.21 
.•.•.•.•.•.•.•.•.•. .!1?~~ .. 9!I)J!iJj.eJ.t~.'!l!~.ir.:!~t .•.•••.•.•.•.•.•.•.•. 171 ... .:5?:1!~ •.••• PJ~ .•.. 0.pD.3.!!. .• . ~~U.~ .. !~1 :~~ 
q (004_06) (age) (altg) (wt_base) 99 -18.32 34.93 <0.0001 44.64 55.02 
; r (004_06) (age) (altg) (female) 106 (-) -18.82 38.89 <0.0001 45.64 56.29 
~ 8 (004_06) (age) (allg) (wt_3mg6) 98 -29.72 11.31 0.0230 67.45 77.79 
"" 
t (cd4_06) (age) (altg) (wt3m.Jllllsloss3) 85 -16.96 27.48 0.0011 41.91 51.68 
..(f u (004_06) (age) (altg) (biJamaj) 106 (-) -13.32 49.89 <0.0001 34.65 45.30 
v (004_06) (age) (allg) (boICvltamins) 106 -30.52 15.49 0.0038 69.04 79.70 
.•.•.•.•.•. ~ ...... .!~ .. 9!I)J!liI~J.t&!\jI)Jd.4t .. ~.Pt .....•...•.•.•.•...•. 1!l!S ... .:2~:!? .• . ~!~CX1 .•. ~~CX1'?1 ... ~!;~ ... !l! ~~. 
x (004_06) (age) (allg) (wt3m.,Prasloss3) (Wt...base) 60 -12.47 32.86 <0.0001 34.94 46.85" 
Y (004_06) (age) (allg) (wt3m.,Prasloss3) (wt_3mg6) 80 -14.20 29.40 <0.0001 38.41 50.32 
(004_06) (age) (allg) (wt3mJll'llsloss3) 
z (bod_vllamlns) 85 ·15.67 30.06 <0.0001 41.33 53.55 
(004 06) (age) (allg) (wt3m .Pra5loss3) (d4t 80) 85 -13.89 33.61 <0.0001 37.78 50.00 
"model starts becommg unstable (big standard deVIations); .. Mode/Instability; none of the Interactions WMI significant 
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Table 3: Model building with clinical parameters during follow-up assessments 
Log prob 
Step Model Variables obs likelihood chl2 >chi2 AIC SIC 
constant a case 213 -79.02 
; b cd4_nadir" 196 -68.20 0.96 0.3265 138,39 141.05 
... c WHOstaget 209 -77.52 0.00 0.9501 157,03 160.38 1 .... , ....... e. •...•. ~ ..•.•...............•.•.•.•. ".'.'.'.""' • . g..0} •. :!H~ ..... l ~~~ .... 9P.l. ~ ... !~:~ .. J?!:?!. 
§ interactions f (cd4 n) (age) 177 -61.79 5.91 0.0520 127.57 133.92 9 (cd4_n) (age) (cd4.Jltage) 177 61.43 6.62 0,0851 128.86 138.39 
h (cd4_n) (age) (wCbase) 162 46.96 24.58 <0.0001 99.92 109.18 
I (cd4_n) (age) (female) 177 -49.90 29.69 <0.0001 105.79 115.32 
J (cd4_n) (age) (1Nt_3mg6) 156 -52.72 8.66 0.0342 111,44 120.59 
k (cd4_n) (age) (wI3m,..l)l'esloss3) 146 -37.29 30.50 <0.0001 80.57 89.52 
I (cd4_n) (age) (bUamaj) 177 -31.92 65.64 <0.0001 69.84 79.36 
m (cd4_n) (age) (bLhiv) 177 -61.55 6.38 0.0946 129,10 138.63 
n (OO4_n) (age) (bUaminor) 177 -51.96 25.56 <0.0001 109.92 119,45 
0 (cd4_n) (age) (bLcomorb) 177 -61.69 6.10 0.1068 129.38 138.91 
P (cd4_n) (age) (bpnp) 177 -49.98 29.52 <0.0001 105.96 115,48 
q (cd4_n) (age) (blipo) 177 -60.83 7.82 0.0499 127.66 137.19 
r (cd4_n) (age) (b_vltamlns) 177 -57.68 13.76 0.0033 121.72 131.25 
II (OO4.Jl) (age) (d4'-60) 177 -48.41 32.66 <0.0001 102.82 112.35 
t (cd4_n) (age) (d4C80) 177 -43.89 41.71 <0.0001 93.77 103,30 
.•. _' _. _ ,_ • ..L! _. _ ••• l~_nl.~>'<~f)_~.9)J~l. •.•.•. _. _ .• ' •.• '. , •.•. J!L. :?!I:Q8.,., ~~~~ .•.• (l.~C! .•. !~~ . .t6 •. ~~J:~~ 
II (cd4_n) (age) (bijamaj) (wi_base) 162 -26.75 65.00 <0.0001 61.50 73.85 
w (cd4_n) (age) (bljamaj) (female) 177 -24.84 79.80 <0.0001 57.68 70.38 
x (cd4_n) (age) (bijamaj) (1Nt_3mg6) 156 -28.81 56.49 <0.0001 65.61 77.81 
Y (cd4_n) (age) (bijamaj) (wI3mJlfllsloss3) 122 -23.81 57.46 <0.0001 55.82 67,55 
z (cd4_n) (age) (bljamaj) (bLhlv) 177 -31.71 66,05 <0.0001 71.43 84.13 
sa (cd4_n) (age) (bljamaj) (bljaminor) 177 -31.71 66.07 <0.0001 71.41 84.12 
bb (cd4_n) (age) (bijamaj) (bU:omorb) 177 -30.06 69.36 <0.0001 68.12 80.82 j cc (cd4_n) (age) (bijamaj) (bpnp) 177 -28.78 71,92 <0.0001 65.56 78.27 del (cd4_n) (age) (bUamaj) (btipo) 177 -30.97 67,64 <0.0001 69.94 82.64 
:.< (cd4_n) (age) (bljamaj) (b_vitamins) 177 -30,55 68.38 <0,0001 69.10 81.80 ,l! .. 
ff (cd4_n) (age) (bljamaj) (d4t_60) 177 -29.51 70.46 <0.0001 67.02 79,73 
99 (cd4_n) (age) (bijamaj) (d4'-80) 177 -28.72 72.05 <0.0001 65.43 78.14 
•.• , •...•.•. !I~ ..... l~_~H!!9~)j!i...J!I~U.l~l. •...•.• ' •. _ ........ , .. m .. , :~'.¥! .... ~~~~~ ... ::O~~! ... ~?~~q .• . ..s.o.:~P. 
B (cd4_n) (age) (bijamaj) (lNt_base) (lNt3m,..l)l'es1oss3) 132 -20.80 53.30 <0.0001 51.60 66.01 
II (cd4_n) (age) (bijamaj) (female) (1Nt3m..,Pl'8llloss3) 146 -18.58 67.92 <0,0001 47.19 62,08 
(cd4_n) (age) (bijamaj) (1Nt_3mg6) 
nn (1Nt3mJlresloss3) 127 -20,10 51.48 <0,0001 50.21 64.43 
pp (cd4_n) (age) (bijamaj) (bi_hiv) (INt3m,..l)l'esI0ss3) 146 -23,52 58.04 <0,0001 57.04 71.96 
(cd4_n) (age) (bljamaj) (bljaminor) 
rr (1Nt3mJlresloss3) 146 -23,81 57,46 <0,0001 57,61 72.53 
(cd4_n) (age) (bijamaj) (bLcomorb) 
tt (1Nt3mJlrealoss3) 146 -22.51 60.05 <0.0001 55,03 69.85 
VY (OO4_n) (age) (bljamaj) (bpnp) (INt3mJlfllsloss3) 146 -21,95 61.18 <0.0001 53,90 68.81 
xx (cd4_n) (age) (bi_lamaj) (blipo) (1Nt3mJlresloss3) 146 -22.66 59.76 <0,0001 55.32 70,24 
(cd4_n) (age) (bijamaj) (b_vitamins) 
L....- _ .•. , , •.• , •. ~., •.•. {~~!!lJ!l!l~~~} •.•.•.•.•.•.• ,.,., •.•.•.•.•.•.• , 1~~, •. :~,.I!~., •. ~~"~'!. .•. ::~,"~1. _. ~?J!'!.. _ .!p" 7~, 
*continued on next page 
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*Table continued from previous page 
-
Log prob 
Step Model Variables obs likelihood chi2 >chi2 AIC BIC 
(cd4_n) (age) (biJamaj) (female) (wt_base) 
bbb (wt3m-presloss3) 132 -16.48 61.94 <0.0001 44.96 62.26 
(cd4_n) (age) (bUamaj) (female) (wt_3mg6) 
ddd (wt3m.Jll8sloss3) 127 -14.89 61.89 <0.0001 41.79 58.85 
(cd4_n) (age) (bUamaj) (female) \(bLhiv) 
fff (wt3m-Plesloss3) 146 -18.53 68.01 <0.0001 49.06 66.97 
(cd4_n) (age) (biJamaj) (female) (biJaminor) 
hhh (wt3m-presloss3) 146 -18.47 68.13 <0.0001 48.94 66.84 
(cd4_n) (age) (bi_lamaj) (female) (bi_comorb) 
W (wt3m-presloss3) 146 -16.95 71.18 <0.0001 45.90 63.80 
(cd4_n) (age) (biJamaj) (female) (bpnp) 
III (wt3m-presloss3) 146 -17.11 70.85 <0.0001 46.23 64.13 
(cd4_n) (age) (biJamaj) (female) (blipo) 
nnn (wt3 m.Jll8sloss3) 146 -17.14 70.80 <0.0001 46.28 64.18 
(cd4_n) (age) (biJamaj) (female) (b_vitamins) 
_. _._. _._. _. PP..P._. _ .1~~I!I~~!C?!~~L. _. _. _. _. _. _. _. _. _. _. _. _. _. _. _. !~. _. :E·.~9 _. _ .~~"9Q. _. -;~"qQQ!. _. ~?" 1r. _. J.5~0? 
(cd4_n) (age) (biJamaj) (female) (wt_3mg6) 
m (wt3m-presloss3) (wt_base) 127 -14.39 62.90 <0.0001 42.78 62.69 
(cd4_n) (age) (biJamaj) (female) (wt_3mg6) 
r! tit (wt3m-presloss3) (b_hiv) 127 -14.68 62.32 <0.0001 43.36 63.27 
1 (cd4_n) (age) (biJamaj) (female) (wt_3mg6) 
... YVV (wt3m-presloss3) (bJaminor) 127 -14.55 62.58 <0.0001 43.10 63.01 
.. 
·c (cd4_n) (age) (biJamaj) (female) (wt_3mg6) 
xxx (wt3m...J)l'esloss3) (b_comOrb) 127 -13.36 64.96 <0.0001 43.33 63.23 
(cd4_n) (age) (biJamaj) (female) (wt_3mg6) 
zzz (wt3m.Jll'8Sloss3) (bpnp) 127 -14.45 62.77 <0.0001 42.91 62.82 
(cd4_n) (age) (biJamaj) (female) (wt_3mg6) 
bbbb (wt3m-presloss3) (blipo) 127 -14.04 63.60 <0.0001 42.08 62.00 
(cd4_n) (age) (biJamaj) (female) (wt_3mg6) 
_._._._._._.!I~J!!!._.("lI!.~(!l..J!f!I.s.!C?!"~I!~_~ll[l!i!,~.l._._._._._._._._._._.1??_.:1~,~_._.§?"~._.~~"qQQ!._.~?}~._.J.2~6~. 
_e (cd4_n) (biJamaj) (wt_3mg6) (wt3m.Jll8s1oss3)** 127 -19.10 53.46 <0.0001 50.20 
(cd4_n) (biJamaj) (wt_3mg6) (wt3m-presloss3) 
hhhh (b_hiv) 127 -19.97 51.74 <0.0001 51.94 
(cd4_n) (biJamaj) (wt_3mg6) (wt3m.Jll8s1oss3) 
WI (bJaminor) 127 -20.05 51.95 <0.0001 52.09 
(cd4_n) (biJamaj) (wt_3mg6) (wt3m-presloss3) 
1111 (b_comorb) 127 -19.90 51.89 <0.0001 51.79 
(cd4_n) (biJamaj) (wt_3mg6) (wt3m-presloss3) 
nnnn (bpnp) 127 -19.15 53.38 <0.0001 50.30 
(cd4_n) (biJamaj) (wt_3mg6) (wt3m-presloss3) 
pppp (blipo) 127 -19.25 53.18 <0.0001 50.50 
(cd4_n) (biJamaj) (wt_3mg6) (wt3m-presloss3) 
rrrr (b vitamins) 127 -19.71 52.27 <0.0001 51.41 
Interactions (cd4_n) (biJamaj) (wt_3mg6) (wt_base) 
kkkkk (wt3m .JIf'8sloss3) (wt base*wt3m .,preslos3) 127 -9.76 72.16 <0.0001 37.52 
Note: * cd4_nadir, whostage wel8 coIlmear, so the strongest venable, by companng AIC and BIC wes chosen; 
- female and age dtopped from the model dua to insfability, BIC and AIC inCl88sed dua to less vanablas 
-only the above lisfed intel8c1ion variabla sig'llfieantJy hed an impact when placed witlin the model, however 
it did not have a big anough impact to wananf it's inclusion. It slightly lowal8d odds I8tios that wal8 axtramaly 
inflated when including the intal8c1ion 
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